NAME,DESCRIPTION,SEQAPASS,GENE_SYMBOLS,GENE_NAMES,GENE_URLS,AOP,EVENT,HIT_CALL,TOP,SCALED_TOP,AC50,LOGAC50,BMAD,MAXMED,MAXMED_UNITS,MAXMEDCONC,CUTOFF,FLAGS,MODLACC,MODLAC10,MODLACB,STOCK_CONCENTRATION,INTENDED_TARGET_FAMILY
ACEA_AR_agonist_AUC_viability,"Data from the assay component ACEA_AR_AUC_viability was analyzed  in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of growth reporter, loss-of-signal activity can be used to understand changes in the viability. 
Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cell cycle"" intended target family, where the subfamily is ""cytotoxicity"".",, , , ,,,Active,175.220510106629,6.521188463784047,61.6766483136597,1.79012076487375,8.95647120560566,145.767965658194,percent_activity,2,26.869413616817,"[""Only highest conc above baseline, active"",""Only highest conc above baseline, active""]",1.56588771433342,1.56588771433342,1.50176050016873,20,cell cycle
ACEA_AR_antagonist_80hr,"Data from the assay component ACEA_AR_antagonist_80hr was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of growth reporter, measures of the cells for loss-of-signal activity can be used to understand the signaling at the pathway-level as they relate to the gene AR. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""nuclear receptor"" intended target family, where the subfamily is ""steroidal"".",, , , ,,,Active,3.43183828933549,9.375372761083819,54.51386671873279,1.73650698802752,0.122016065451132,2.85986524216955,log2_fold_induction,2,0.366048196353396,"[""Only highest conc above baseline, active"",""Only highest conc above baseline, active""]",1.38818343287233,1.38818343287233,1.3763946904858,20,nuclear receptor
ACEA_AR_antagonist_AUC_viability,"Data from the assay component ACEA_AR_antagonist_AUC_viability was analyzed  in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of growth reporter, loss-of-signal activity can be used to understand changes in the viability. 
Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cell cycle"" intended target family, where the subfamily is ""cytotoxicity"".",, , , ,,,Active,159.073708858121,5.494625361686901,48.31240303495581,1.68405863961581,9.65026114229828,131.24388907977,percent_activity,2,28.9507834268948,"[""Only highest conc above baseline, active"",""Only highest conc above baseline, active""]",1.37530075425452,1.37530075425452,1.23265242794031,20,cell cycle
ACEA_ER_AUC_viability,"Data from the assay component ACEA_ER_AUC_viability was analyzed  in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of growth reporter, loss-of-signal activity can be used to understand changes in the viability. 
Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cell cycle"" intended target family, where the subfamily is ""cytotoxicity"".",, , , ,,,Active,114.89258370575455,5.744629185287727,70.5580533696775,1.8485465905128038,5.860768439731081,95.38130114740031,percent_activity,2,20,"[""Only highest conc above baseline, active""]",1.6999441698473512,1.6852464638099,1.6388419624092112,20,cell cycle
ATG_Ahr_CIS_up,"Data from the assay component ATG_Ahr_CIS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_Ahr_CIS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene AHR. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the dna binding intended target family, where the subfamily is basic helix-loop-helix protein.",NP_001612.1, , , ,"[131,21,57,310,41,150,57,131,21,41,150,310]",[165],Active,1.805938204956813,1.8229338910642463,2.34776774065209,0.3706551309306144,0.19813534805724511,2.0301469634624087,log2_fold_induction,1.84509804001426,0.9906767402862255,,0.6527719697750369,-0.6601839700952729,-2.81015323346533,20,dna binding
ATG_AP_1_CIS_up,"Data from the assay component ATG_AP_1_CIS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_AP_1_CIS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene FOS and JUN. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the dna binding intended target family, where the subfamily is basic leucine zipper.","NP_005243.1|NP_002219.1", , , ,,,Active,1.5802020871043077,2.6345740372009003,44.03093972973523,1.64375795448254,0.11995882938125292,1.532960654059261,log2_fold_induction,2.30102999566398,0.5997941469062646,,1.5524218890680317,1.4167827706574772,1.2353470875712866,20,dna binding
ATG_BRE_CIS_up,"Data from the assay component ATG_BRE_CIS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_BRE_CIS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene SMAD1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the dna binding intended target family, where the subfamily is Smad protein.",NP_005891.1, , , ,,,Active,1.4650758840761888,1.5997498849474245,68.24968407016485,1.8341006453552604,0.183163117917566,1.4648037376867586,log2_fold_induction,2.30102999566398,0.91581558958783,,1.8618544227934377,1.8063830822599019,1.7148201206351776,20,dna binding
ATG_DR4_LXR_CIS_dn,ATG_DR4_LXR_CIS_dn was not developed or optimized to detect loss of signal. Use data with caution.,"NP_009052.3|NP_005684.2", , , ,,,Active,2.0971603428691408,3.545490806260794,35.08237540224014,1.5450889914545258,0.11830014277097414,1.747636947372842,log2_fold_induction,1.84509804001426,0.5915007138548707,,1.3664632045093152,1.2408991807348622,1.1250193083794813,20,nuclear receptor
ATG_E2F_CIS_dn,ATG_E2F_CIS_dn was not developed or optimized to detect loss of signal. Use data with caution.,NP_005216.1, , , ,,,Active,0.5713857776596557,1.1874870710249714,37.44939069285586,1.5734447560572966,0.0962344418902124,0.6254145444584512,log2_fold_induction,1.84509804001426,0.481172209451062,"[""Less than 50% efficacy"",""Borderline active""]",1.6643233405029403,1.5745888731775923,1.4541644423736126,20,dna binding
ATG_ERa_TRANS_up,"Data from the assay component ATG_ERa_TRANS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_ERa_TRANS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene ESR1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.",NP_000116.2, , , ,"[200,29,165,53,52,167,112,30,67,200,29,165,53,52,30,67,112,167]",[1181],Active,3.191125572825098,2.8874963355428602,20.172983339237053,1.3047701298418328,0.22103062321117403,3.0476760005418364,log2_fold_induction,1.84509804001426,1.10515311605587,,1.2702843484886803,1.2321189500595362,1.1854897583653439,20,nuclear receptor
ATG_ERE_CIS_up,"Data from the assay component ATG_ERE_CIS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_ERE_CIS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene ESR1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.",NP_000116.2, , , ,"[200,29,165,53,52,167,112,30,67,200,29,165,53,52,30,67,112,167]",[1181],Active,1.971837811259416,3.9022297446387775,34.33335977938995,1.5357163045109088,0.10106210757931403,1.6431981760616585,log2_fold_induction,1.84509804001426,0.5053105378965701,,1.328318607158624,1.2037521736481147,1.1080221111361837,20,nuclear receptor
ATG_Ets_CIS_dn,ATG_Ets_CIS_dn was not developed or optimized to detect loss of signal. Use data with caution.,NP_005229.1, , , ,,,Active,0.43892344607136347,1.2114402738918209,102.8820764806347,2.012339721083459,0.07246307647694375,0.3657695384828537,log2_fold_induction,2.30102999566398,0.3623153823847187,"[""Less than 50% efficacy"",""Borderline active"",""Only one conc above baseline, active""]",2.3076846107988467,2.0087496081437357,1.5946966905501243,20,dna binding
ATG_GATA_CIS_dn,ATG_GATA_CIS_dn was not developed or optimized to detect loss of signal. Use data with caution.,NP_002040.1, , , ,,,Active,0.3977034465318296,1.2127581575238116,163.59746628065375,2.213776573242078,0.06558660423177091,0.33141954386465955,log2_fold_induction,2.30102999566398,0.3279330211588546,"[""Only one conc above baseline, active"",""Less than 50% efficacy"",""Borderline active"",""Hit-call potentially confounded by overfitting""]",2.297806268666228,2.212634131469251,2.0944742915484205,20,dna binding
ATG_GLI_CIS_up,"Data from the assay component ATG_GLI_CIS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_GLI_CIS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene GLI1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the dna binding intended target family, where the subfamily is zinc finger.",NP_005260.1, , , ,,,Active,0.532916882541645,1.3862577688818067,77.0756129980838,1.8869169874449494,0.07688568381788191,0.5326414655910703,log2_fold_induction,2.30102999566398,0.38442841908940956,"[""Less than 50% efficacy"",""Only one conc above baseline, active""]",1.9385583077459352,1.872239998285624,1.7676344245751021,20,dna binding
ATG_IR1_CIS_dn,ATG_IR1_CIS_dn was not developed or optimized to detect loss of signal. Use data with caution.,NP_001193922.1, , , ,,,Active,1.132312174000634,2.31144038752117,36.869262852526724,1.566664454604209,0.09797459455270192,0.9435934785709625,log2_fold_induction,1.84509804001426,0.4898729727635096,"[""Hit-call potentially confounded by overfitting""]",1.519383477423223,1.3838783588986714,1.1834961123735783,20,nuclear receptor
ATG_ISRE_CIS_dn,ATG_ISRE_CIS_dn was not developed or optimized to detect loss of signal. Use data with caution.,NP_002189.1, , , ,,,Active,1.0669390725890118,1.5090569211277407,39.18159264627968,1.5930820851409306,0.14140474857524557,0.889115893880543,log2_fold_induction,1.84509804001426,0.7070237428762278,,1.6998164970942868,1.5274036112420737,1.2457463960625708,20,dna binding
ATG_MRE_CIS_up,"Data from the assay component ATG_MRE_CIS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_MRE_CIS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene MTF1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the dna binding intended target family, where the subfamily is zinc finger.",NP_005946.2, , , ,,,Active,1.8716940715058432,3.1120624804046715,102.82318705750606,2.0120910609202136,0.12028640705584168,1.559745147860073,log2_fold_induction,2.30102999566398,0.6014320352792084,,1.8717497704328023,1.743309077005216,1.5996585493857893,20,dna binding
ATG_NFI_CIS_up,"Data from the assay component ATG_NFI_CIS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_NFI_CIS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene NFIA. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the dna binding intended target family, where the subfamily is nuclear factor I.",NP_001128145.1, , , ,,,Active,0.8554039535374038,2.0304897907407264,74.04189884248952,1.8694775479285264,0.08425592262892893,0.8550980239289047,log2_fold_induction,2.30102999566398,0.4212796131446447,,1.8678470793177857,1.8223106586116111,1.75019672774526,20,dna binding
ATG_NRF1_CIS_up,"Data from the assay component ATG_NRF1_CIS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_NRF1_CIS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene NRF1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the dna binding intended target family, where the subfamily is nuclear respiratory factors.",NP_005002.3, , , ,,,Active,0.5202813354521563,1.2940230047292733,163.65422662016377,2.2139272261066596,0.08041299629924369,0.43356778207371166,log2_fold_induction,2.30102999566398,0.40206498149621844,"[""Only one conc above baseline, active"",""Less than 50% efficacy"",""Hit-call potentially confounded by overfitting"",""Borderline active""]",2.280383896490341,2.2060238836692005,2.0946391324293354,20,dna binding
ATG_NRF2_ARE_CIS_up,"Data from the assay component ATG_NRF2_ARE_CIS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_NRF2_ARE_CIS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene NFE2L2. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the dna binding intended target family, where the subfamily is basic leucine zipper.",NP_006155.2, , , ,"[61,61]",[478],Active,2.0411944158971838,2.6284119494792573,24.77722842001859,1.3940527245900254,0.15531769411576343,2.1880351552255966,log2_fold_induction,1.84509804001426,0.7765884705788172,,1.3675821894966287,1.327927110807474,1.274772410840318,20,dna binding
ATG_Oct_MLP_CIS_up,"Data from the assay component ATG_Oct_MLP_CIS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_Oct_MLP_CIS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene POU2F1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the dna binding intended target family, where the subfamily is POU domain protein.",NP_002688.3, , , ,,,Active,1.92413697792894,2.839257839089183,110.12416854049384,2.0418826424222507,0.13553802345377633,1.6034474816400794,log2_fold_induction,2.30102999566398,0.6776901172688816,,1.9420946925337783,1.8262181982648564,1.6820694526473927,20,dna binding
ATG_PPARg_TRANS_up,"Data from the assay component ATG_PPARg_TRANS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_PPARg_TRANS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene PPARG. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.",NP_056953.2, , , ,"[72,36,58,34,163,34,36,58,72,163]",,Active,2.850047259451311,2.48377660973324,57.23957623732005,1.7576964098802828,0.2294930428350727,2.3750394313469245,log2_fold_induction,1.84509804001426,1.1474652141753636,,1.736267423934381,1.695563674818153,1.6383719898823976,20,nuclear receptor
ATG_PXRE_CIS_up,"Data from the assay component ATG_PXRE_CIS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_PXRE_CIS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene NR1I2. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.",NP_071285.1, , , ,"[8,11,60,8,11,60]",,Active,3.3496447670076854,5.026439688127134,6.337427429854921,0.8019129992456909,0.13328100901796647,2.7913706391764426,log2_fold_induction,1.30102999566398,0.6664050450898323,,0.3752770959268458,0.18980234776114047,0.12890944735738963,20,nuclear receptor
ATG_PXR_TRANS_up,"Data from the assay component ATG_PXR_TRANS was analyzed into 1 assay endpoint. This assay endpoint, ATG_PXR_TRANS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene NR1I2. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.",NP_071285.1, , , ,"[8,11,60,8,11,60]",,Active,2.5012632760235185,1.9419013024183607,4.340210548131505,0.6375107981009277,0.2576097222766731,3.1495953968793624,log2_fold_induction,1.84509804001426,1.2880486113833656,,0.6514507747695828,0.4500492584952334,0.1257846319803716,20,nuclear receptor
ATG_RXRb_TRANS_up,"Data from the assay component ATG_RXRb_TRANS was analyzed into 1 assay endpoint. This assay endpoint, ATG_RXRb_TRANS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene RXRB. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.",NP_068811.1, , , ,,,Active,5.084029908323973,5.117828577380043,24.10043785123236,1.382024932809173,0.19867917932204862,5.144258796958034,log2_fold_induction,1.84509804001426,0.9933958966102431,,1.27515615619652,1.2295845824208806,1.2161163676977886,20,nuclear receptor
ATG_Sp1_CIS_up,"Data from the assay component ATG_Sp1_CIS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_Sp1_CIS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene SP1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the dna binding intended target family, where the subfamily is zinc finger.",NP_612482.2, , , ,"[148,148]",,Active,1.1981037620170145,2.2803797532245746,71.5018880600632,1.854317509818435,0.10507931938290839,1.1197079407858876,log2_fold_induction,2.30102999566398,0.525396596914542,,1.8128048166527932,1.681343624145015,1.4852694373214126,20,dna binding
ATG_SREBP_CIS_up,"Data from the assay component ATG_SREBP_CIS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_SREBP_CIS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene SREBF1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the dna binding intended target family, where the subfamily is basic helix-loop-helix leucine zipper.",NP_004167.3, , , ,"[62,61,58,34,34,62,61,58]",,Active,0.9427150309436281,2.594565635041397,72.4104005273048,1.859800949722207,0.07266842805682862,0.9341588296190075,log2_fold_induction,2.30102999566398,0.3633421402841431,,1.8159307853223918,1.746858462279837,1.6532164653544315,20,dna binding
ATG_VDRE_CIS_up,"Data from the assay component ATG_VDRE_CIS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_VDRE_CIS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene VDR. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.",NP_000367.1, , , ,,,Active,0.838853882534359,1.155167012451249,4.6434691032598545,0.666842560182664,0.1452350826317871,0.8369499366807397,log2_fold_induction,1.30102999566398,0.7261754131589355,"[""Borderline active""]",1.4569259301265136,0.6997733487919328,-0.2648561262986072,20,nuclear receptor
ATG_Xbp1_CIS_up,"Data from the assay component ATG_Xbp1_CIS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_Xbp1_CIS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene XBP1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the dna binding intended target family, where the subfamily is basic leucine zipper.",NP_005071.2, , , ,,,Active,0.9291929312624749,1.5775394130672495,87.16380035332561,1.9403361572843794,0.11780281666064009,0.8403352942721984,log2_fold_induction,2.30102999566398,0.5890140833032005,"[""Only one conc above baseline, active""]",2.0284806130863986,1.861964980340234,1.5875479652566666,20,dna binding
BSK_3C_Eselectin_down,"Data from the assay component BSK_3C_Eselectin was analyzed into 2 assay endpoints. This assay endpoint, BSK_3C_Eselectin_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene SELE. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cell adhesion molecules"" intended target family, where the subfamily is ""selectins"".",NP_000441.2, , , ,,,Active,0.19016087094475975,2.401589775821215,39.99999999999999,1.6020599913279623,0.022749058062569997,0.150052765,log10_fold_induction,1.60205999132796,0.07918124604762482,"[""Only one conc above baseline, active"",""Less than 50% efficacy""]",1.6020599913279623,1.6020599913279623,1.4111298699730122,20,cell adhesion molecules
BSK_3C_HLADR_down,"Data from the assay component BSK_3C_HLADR was analyzed into 2 assay endpoints. This assay endpoint, BSK_3C_HLADR_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene HLA-DRA. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cell adhesion molecules"" intended target family, where the subfamily is ""MHC Class II"".",NP_061984.2, , , ,,,Active,0.4587022479944754,5.793066804209947,39.99999999999999,1.6020599913279623,0.025758990402599997,0.412923215,log10_fold_induction,1.60205999132796,0.07918124604762482,"[""Only one conc above baseline, active"",""Less than 50% efficacy""]",1.6020599913279623,1.6020599913279623,0.9824157806838956,20,cell adhesion molecules
BSK_3C_IL8_down,"Data from the assay component BSK_3C_IL8 was analyzed into 2 assay endpoints. This assay endpoint, BSK_3C_IL8_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene CXCL8. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cytokine"" intended target family, where the subfamily is ""interleukins"".",NP_000575.1, , , ,,,Active,0.47892929000107,4.848362793750529,39.99999999999999,1.6020599913279623,0.0329272175904,0.35065359,log10_fold_induction,1.60205999132796,0.0987816527712,"[""Only one conc above baseline, active"",""Less than 50% efficacy""]",1.6020599913279623,1.6020599913279623,1.448151191539422,20,cytokine
BSK_3C_MCP1_down,"Data from the assay component BSK_3C_MCP1 was analyzed into 2 assay endpoints. This assay endpoint, BSK_3C_MCP1_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene CCL2. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cytokine"" intended target family, where the subfamily is ""chemotactic factor"".",NP_002973.1, , , ,,,Active,0.5560434719758046,6.559953799036607,39.99999999999999,1.6020599913279623,0.028254440453399997,0.58852793,log10_fold_induction,1.60205999132796,0.08476332136019998,"[""Only one conc above baseline, active"",""Less than 50% efficacy""]",1.6020599913279623,1.6020599913279623,1.0991094609327778,20,cytokine
BSK_3C_Proliferation_down,"Data from the assay component BSK_3C_Proliferation was analyzed into 2 assay endpoints. 
This assay endpoint, BSK_3C_Proliferation_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of viability reporter, measures of total protein for loss-of-signal activity can be used to understand the viability at the cellular-level. 
Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cell cycle"" intended target family, where the subfamily is ""cytotoxicity"".",, , , ,,,Active,0.4293588657833114,3.6555715485932465,39.99999999999999,1.6020599913279623,0.0391510930713,0.327685965,log10_fold_induction,1.60205999132796,0.1174532792139,"[""Less than 50% efficacy"",""Only one conc above baseline, active""]",1.6020599913279623,1.6020599913279623,0.8394544436527169,20,cell cycle
BSK_3C_SRB_down,"Data from the assay component BSK_3C_SRB was analyzed into 2 assay endpoints. 
This assay endpoint, BSK_3C_SRB_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of viability reporter, measures of total protein for loss-of-signal activity can be used to understand the viability at the cellular-level. 
Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cell cycle"" intended target family, where the subfamily is ""cytotoxicity"".",, , , ,,,Active,0.340875522663421,4.305003263757633,39.99999999999999,1.6020599913279623,0.02172150128694,0.34069475,log10_fold_induction,1.60205999132796,0.07918124604762482,"[""Only one conc above baseline, active"",""Less than 50% efficacy""]",1.6020599913279623,1.6020599913279623,1.0730331362932122,20,cell cycle
BSK_3C_uPAR_down,"Data from the assay component BSK_3C_uPAR was analyzed into 2 assay endpoints. This assay endpoint, BSK_3C_uPAR_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene PLAUR. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cytokine"" intended target family, where the subfamily is ""plasmogen activator"".",NP_002650.1, , , ,,,Active,0.24562651122142876,2.0950276777939036,39.99999999999999,1.6020599913279623,0.0390808697223,0.198825485,log10_fold_induction,1.60205999132796,0.1172426091669,"[""Less than 50% efficacy"",""Only one conc above baseline, active""]",1.6020599913279623,1.6020599913279623,1.4041617171616587,20,cytokine
BSK_3C_VCAM1_down,"Data from the assay component BSK_3C_VCAM1 was analyzed into 2 assay endpoints. This assay endpoint, BSK_3C_VCAM1_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene VCAM1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cell adhesion molecules"" intended target family, where the subfamily is ""Immunoglobulin CAM"".",NP_001069.1, , , ,,,Active,0.22708984798368315,2.8679751749182674,39.99999999999999,1.6020599913279623,0.0189344513925,0.185131375,log10_fold_induction,1.60205999132796,0.07918124604762482,"[""Less than 50% efficacy"",""Only one conc above baseline, active""]",1.6020599913279623,1.6020599913279623,0.8885671361176144,20,cell adhesion molecules
BSK_3C_Vis_down,"Data from the assay component BSK_3C_Vis was analyzed into 2 assay endpoints. This assay endpoint, BSK_3C_Vis_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of morphology reporter, loss-of-signal activity can be used to understand changes in the background control. 
Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a background control function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cell morphology"" intended target family, where the subfamily is ""cell conformation"".",, , , ,,,Active,0.1499264807961812,1.893459477841578,39.99999999999999,1.6020599913279623,0,0.124938734,log10_fold_induction,1.60205999132796,0.07918124604762482,"[""Less than 50% efficacy""]",1.6020599913279623,1.6020599913279623,1.3953364013358336,20,cell morphology
BSK_4H_Eotaxin3_down,"Data from the assay component BSK_4H_Eotaxin3 was analyzed into 2 assay endpoints. This assay endpoint, BSK_4H_Eotaxin3_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene CCL26. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cytokine"" intended target family, where the subfamily is ""chemotactic factor"".",NP_006063.1, , , ,,,Active,0.22717341580022848,2.793211988721239,39.99999999999999,1.6020599913279623,0.027110177186399995,0.156588422,log10_fold_induction,1.60205999132796,0.08133053155919999,"[""Less than 50% efficacy"",""Only one conc above baseline, active""]",1.6020599913279623,1.6020599913279623,1.0219911552823615,20,cytokine
BSK_4H_Pselectin_down,"Data from the assay component BSK_4H_Pselectin was analyzed into 2 assay endpoints. This assay endpoint, BSK_4H_Pselectin_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene SELP. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cell adhesion molecules"" intended target family, where the subfamily is ""selectins"".",NP_002996.2, , , ,,,Active,0.2762852848743412,2.2537312000452707,39.99999999999999,1.6020599913279623,0.04086338910171,0.21904570499999998,log10_fold_induction,1.60205999132796,0.12259016730513,"[""Only one conc above baseline, active"",""Less than 50% efficacy""]",1.6020599913279623,1.6020599913279623,1.4099340942088734,20,cell adhesion molecules
BSK_4H_SRB_down,"Data from the assay component BSK_4H_SRB was analyzed into 2 assay endpoints. 
This assay endpoint, BSK_4H_SRB_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of viability reporter, measures of total protein for loss-of-signal activity can be used to understand the viability at the cellular-level. 
Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cell cycle"" intended target family, where the subfamily is ""cytotoxicity"".",, , , ,,,Active,0.08286513008590819,1.0465247040450418,39.99999999999999,1.6020599913279623,0.02048812375239,0.082812898,log10_fold_induction,1.60205999132796,0.07918124604762482,"[""Only one conc above baseline, active"",""Borderline active"",""Less than 50% efficacy""]",1.6020599913279623,1.6020599913279623,1.0826153451601175,20,cell cycle
BSK_4H_VCAM1_down,"Data from the assay component BSK_4H_VCAM1 was analyzed into 2 assay endpoints. This assay endpoint, BSK_4H_VCAM1_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene VCAM1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cell adhesion molecules"" intended target family, where the subfamily is ""Immunoglobulin CAM"".",NP_001069.1, , , ,,,Active,0.19276059590099714,2.434422360378848,39.99999999999999,1.6020599913279623,0.0228833401839,0.14830021999999998,log10_fold_induction,1.60205999132796,0.07918124604762482,"[""Less than 50% efficacy"",""Only one conc above baseline, active""]",1.6020599913279623,1.6020599913279623,0.4631664927313528,20,cell adhesion molecules
BSK_BE3C_HLADR_down,"Data from the assay component BSK_BE3C_HLADR was analyzed into 2 assay endpoints. This assay endpoint, BSK_BE3C_HLADR_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene HLA-DRA. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cell adhesion molecules"" intended target family, where the subfamily is ""MHC Class II"".",NP_061984.2, , , ,,,Active,0.11772729631585205,1.4868078262502096,39.99999999999999,1.6020599913279623,0.025097172292079997,0.117710495,log10_fold_induction,1.60205999132796,0.07918124604762482,"[""Borderline active"",""Only one conc above baseline, active"",""Less than 50% efficacy"",""Hit-call potentially confounded by overfitting""]",1.6020599913279623,1.6020599913279623,1.0005439964546285,20,cell adhesion molecules
BSK_BE3C_tPA_down,"Data from the assay component BSK_BE3C_tPA was analyzed into 2 assay endpoints. This assay endpoint, BSK_BE3C_tPA_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene PLAT. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""protease"" intended target family, where the subfamily is ""serine protease"".",NP_000921.1, , , ,,,Active,0.15538926740225037,1.1629287007049198,39.99999999999999,1.6020599913279623,0.04453963724175,0.147910515,log10_fold_induction,1.60205999132796,0.13361891172525,"[""Less than 50% efficacy"",""Only one conc above baseline, active"",""Borderline active""]",1.6020599913279623,1.6020599913279623,0.875279028632418,20,protease
BSK_CASM3C_LDLR_up,"Data from the assay component BSK_CASM3C_LDLR was analyzed into 2 assay endpoints. This assay endpoint, BSK_CASM3C_LDLR_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, gain-of-signal activity can be used to understand changes in the signaling as they relate to the gene LDLR. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""misc protein"" intended target family, where the subfamily is ""LDL receptor"".",NP_000518.1, , , ,"[57,57]",,Active,0.10846435512169748,1.3698237971205944,39.99999999999999,1.6020599913279623,0.024506084431499996,0.08861477749999999,log10_fold_induction,1.60205999132796,0.07918124604762482,"[""Borderline active"",""Less than 50% efficacy"",""Only one conc above baseline, active""]",1.6020599913279623,1.6020599913279623,1.4004270589002867,20,misc protein
BSK_CASM3C_Thrombomodulin_up,"Data from the assay component BSK_CASM3C_Thrombomodulin was analyzed into 2 assay endpoints. This assay endpoint, BSK_CASM3C_Thrombomodulin_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, gain-of-signal activity can be used to understand changes in the signaling as they relate to the gene THBD. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""gpcr"" intended target family, where the subfamily is ""rhodopsin-like receptor"".",NP_000352.1, , , ,,,Active,0.20955126615737335,2.089566499386036,39.99999999999999,1.6020599913279623,0.0334281881304,0.18326817,log10_fold_induction,1.60205999132796,0.10028456439120001,"[""Less than 50% efficacy"",""Only one conc above baseline, active""]",1.6020599913279623,1.6020599913279623,0.9695901545004607,20,gpcr
BSK_hDFCGF_CollagenIII_down,"Data from the assay component BSK_hDFCGF_CollagenIII was analyzed into 2 assay endpoints. This assay endpoint, BSK_hDFCGF_CollagenIII_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene COL3A1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cell adhesion molecules"" intended target family, where the subfamily is ""collagen"".",NP_000081.1, , , ,,,Active,0.3112549468922221,2.1990040250474907,10,1,0.047181200117099996,0.31087891,log10_fold_induction,1.60205999132796,0.14154360035129998,"[""Less than 50% efficacy""]",1,1,0.588676208948659,20,cell adhesion molecules
BSK_hDFCGF_IP10_down,"Data from the assay component BSK_hDFCGF_IP10 was analyzed into 2 assay endpoints. This assay endpoint, BSK_hDFCGF_IP10_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene CXCL10. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cytokine"" intended target family, where the subfamily is ""chemotactic factor"".",NP_001556.2, , , ,,,Active,0.28215475716124533,3.488302648595801,10,1,0.0269619913164,0.24719099,log10_fold_induction,1.60205999132796,0.0808859739492,"[""Less than 50% efficacy""]",1,1,0.5435851739741471,20,cytokine
BSK_hDFCGF_MCSF_down,"Data from the assay component BSK_hDFCGF_MCSF was analyzed into 2 assay endpoints. This assay endpoint, BSK_hDFCGF_MCSF_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene CSF1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cytokine"" intended target family, where the subfamily is ""colony stimulating factor"".",NP_000748.3, , , ,,,Active,0.44842826554918763,4.193739245879325,10,1,0.0356426758443,0.37804197,log10_fold_induction,1.60205999132796,0.10692802753289998,"[""Less than 50% efficacy""]",1,1,0.4580056311945412,20,cytokine
BSK_hDFCGF_MMP1_up,"Data from the assay component BSK_hDFCGF_MMP1 was analyzed into 2 assay endpoints. This assay endpoint, BSK_hDFCGF_MMP1_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, gain-of-signal activity can be used to understand changes in the signaling as they relate to the gene MMP1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""protease"" intended target family, where the subfamily is ""matrix metalloproteinase"".",NP_002412.1, , , ,,,Active,0.1017034135869769,1.2793174432532184,10,1,0.026499394689809996,0.10501503000000001,log10_fold_induction,1.60205999132796,0.07949818406942999,"[""Less than 50% efficacy""]",1,1,0.4635207235854266,20,protease
BSK_hDFCGF_PAI1_down,"Data from the assay component BSK_hDFCGF_PAI1 was analyzed into 2 assay endpoints. This assay endpoint, BSK_hDFCGF_PAI1_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene SERPINE1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cytokine"" intended target family, where the subfamily is ""plasmogen activator inhibitor"".",NP_000593.1, , , ,,,Active,0.5197397625025677,3.137808560427517,40.000000000000014,1.6020599913279625,0.055212605920499994,0.323226935,log10_fold_induction,1.60205999132796,0.1656378177615,"[""Less than 50% efficacy""]",1.6020599913279625,1.6020599913279625,0.2841321722192096,20,cytokine
BSK_hDFCGF_Proliferation_down,"Data from the assay component BSK_hDFCGF_Proliferation was analyzed into 2 assay endpoints. 
This assay endpoint, BSK_hDFCGF_Proliferation_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of viability reporter, measures of total protein for loss-of-signal activity can be used to understand the viability at the cellular-level. 
Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cell cycle"" intended target family, where the subfamily is ""cytotoxicity"".",, , , ,,,Active,0.25094281053270173,1.8519275138203344,40.000000000000014,1.6020599913279625,0.0451678604517,0.25093236,log10_fold_induction,1.60205999132796,0.1355035813551,"[""Less than 50% efficacy"",""Only one conc above baseline, active""]",1.6020599913279625,1.6020599913279625,0.9423655931401019,20,cell cycle
BSK_hDFCGF_SRB_down,"Data from the assay component BSK_hDFCGF_SRB was analyzed into 2 assay endpoints. 
This assay endpoint, BSK_hDFCGF_SRB_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of viability reporter, measures of total protein for loss-of-signal activity can be used to understand the viability at the cellular-level. 
Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cell cycle"" intended target family, where the subfamily is ""cytotoxicity"".",, , , ,,,Active,0.11310268068470997,1.4284023847854397,40.000000000000014,1.6020599913279625,0.024374730148650003,0.113072438,log10_fold_induction,1.60205999132796,0.07918124604762482,"[""Only one conc above baseline, active"",""Hit-call potentially confounded by overfitting"",""Less than 50% efficacy""]",1.6020599913279625,1.6020599913279625,1.0366119007856216,20,cell cycle
BSK_hDFCGF_VCAM1_down,"Data from the assay component BSK_hDFCGF_VCAM1 was analyzed into 2 assay endpoints. This assay endpoint, BSK_hDFCGF_VCAM1_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene VCAM1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cell adhesion molecules"" intended target family, where the subfamily is ""Immunoglobulin CAM"".",NP_001069.1, , , ,,,Active,0.36268436889710715,2.5667779132604256,10,1,0.04709982465089999,0.341596175,log10_fold_induction,1.60205999132796,0.14129947395269998,"[""Less than 50% efficacy""]",1,1,0.20540680341684148,20,cell adhesion molecules
BSK_KF3CT_MCP1_down,"Data from the assay component BSK_KF3CT_MCP1 was analyzed into 2 assay endpoints. This assay endpoint, BSK_KF3CT_MCP1_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene CCL2. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cytokine"" intended target family, where the subfamily is ""chemotactic factor"".",NP_002973.1, , , ,,,Active,0.1649404795233586,1.4354593056467868,40.000000000000014,1.6020599913279625,0.0383014409568,0.134601895,log10_fold_induction,1.60205999132796,0.1149043228704,"[""Borderline active"",""Only one conc above baseline, active"",""Less than 50% efficacy"",""Hit-call potentially confounded by overfitting""]",1.6020599913279625,1.6020599913279625,0.8531273419735823,20,cytokine
BSK_LPS_CD40_down,"Data from the assay component BSK_LPS_CD40 was analyzed into 2 assay endpoints. This assay endpoint, BSK_LPS_CD40_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene CD40. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cytokine"" intended target family, where the subfamily is ""inflammatory factor"".",NP_001241.1, , , ,,,Active,0.2444924560143356,1.771316684456937,40.000000000000014,1.6020599913279625,0.0460095510042,0.244479345,log10_fold_induction,1.60205999132796,0.13802865301259998,"[""Only one conc above baseline, active"",""Less than 50% efficacy""]",1.6020599913279625,1.6020599913279625,0.9458213087902463,20,cytokine
BSK_LPS_MCSF_down,"Data from the assay component BSK_LPS_MCSF was analyzed into 2 assay endpoints. This assay endpoint, BSK_LPS_MCSF_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene CSF1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cytokine"" intended target family, where the subfamily is ""colony stimulating factor"".",NP_000748.3, , , ,,,Active,0.23320253991531376,2.2377265572388025,40.000000000000014,1.6020599913279625,0.0347380155633,0.187181465,log10_fold_induction,1.60205999132796,0.1042140466899,"[""Only one conc above baseline, active"",""Less than 50% efficacy""]",1.6020599913279625,1.6020599913279625,0.7016657177041414,20,cytokine
BSK_LPS_VCAM1_down,"Data from the assay component BSK_LPS_VCAM1 was analyzed into 2 assay endpoints. This assay endpoint, BSK_LPS_VCAM1_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene VCAM1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cell adhesion molecules"" intended target family, where the subfamily is ""Immunoglobulin CAM"".",NP_001069.1, , , ,,,Active,0.273437387973687,3.4533099897067006,40.000000000000014,1.6020599913279625,0.0224178208338,0.225193695,log10_fold_induction,1.60205999132796,0.07918124604762482,"[""Only one conc above baseline, active"",""Less than 50% efficacy""]",1.6020599913279625,1.6020599913279625,0.9802782229998319,20,cell adhesion molecules
BSK_SAg_CD38_down,"Data from the assay component BSK_SAg_CD38 was analyzed into 2 assay endpoints. This assay endpoint, BSK_SAg_CD38_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene CD38. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cytokine"" intended target family, where the subfamily is ""other cytokine"".",NP_001766.2, , , ,,,Active,0.26152652120016195,3.302884638148567,40.000000000000014,1.6020599913279625,0.0243080164845,0.261407955,log10_fold_induction,1.60205999132796,0.07918124604762482,"[""Less than 50% efficacy"",""Only one conc above baseline, active""]",1.6020599913279625,1.6020599913279625,1.0647558435898474,20,cytokine
BSK_SAg_CD40_down,"Data from the assay component BSK_SAg_CD40 was analyzed into 2 assay endpoints. This assay endpoint, BSK_SAg_CD40_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene CD40. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cytokine"" intended target family, where the subfamily is ""inflammatory factor"".",NP_001241.1, , , ,,,Active,0.3557457119699685,3.5682139348400557,40.000000000000014,1.6020599913279625,0.0332328459435,0.27545301499999997,log10_fold_induction,1.60205999132796,0.09969853783049999,"[""Only one conc above baseline, active"",""Less than 50% efficacy""]",1.6020599913279625,1.6020599913279625,1.1501559109352908,20,cytokine
BSK_SAg_CD69_down,"Data from the assay component BSK_SAg_CD69 was analyzed into 2 assay endpoints. This assay endpoint, BSK_SAg_CD69_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene CD69. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cytokine"" intended target family, where the subfamily is ""inflammatory factor"".",NP_001772.1, , , ,,,Active,0.1831683598394914,1.72997717272474,40.000000000000014,1.6020599913279625,0.03529302057225,0.142255935,log10_fold_induction,1.60205999132796,0.10587906171674999,"[""Only one conc above baseline, active"",""Less than 50% efficacy""]",1.6020599913279625,1.6020599913279625,0.69524702439928,20,cytokine
BSK_SAg_Eselectin_down,"Data from the assay component BSK_SAg_Eselectin was analyzed into 2 assay endpoints. This assay endpoint, BSK_SAg_Eselectin_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene SELE. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cell adhesion molecules"" intended target family, where the subfamily is ""selectins"".",NP_000441.2, , , ,,,Active,0.5098443259421627,4.442837512247712,40.000000000000014,1.6020599913279625,0.038252154885,0.47222425,log10_fold_induction,1.60205999132796,0.114756464655,"[""Only one conc above baseline, active"",""Less than 50% efficacy""]",1.6020599913279625,1.6020599913279625,0.9978828276696823,20,cell adhesion molecules
BSK_SAg_IL8_down,"Data from the assay component BSK_SAg_IL8 was analyzed into 2 assay endpoints. This assay endpoint, BSK_SAg_IL8_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene CXCL8. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cytokine"" intended target family, where the subfamily is ""interleukins"".",NP_000575.1, , , ,,,Active,0.29652037194152997,1.973965021789586,40.000000000000014,1.6020599913279625,0.050071872038999994,0.24254388999999998,log10_fold_induction,1.60205999132796,0.150215616117,"[""Less than 50% efficacy"",""Only one conc above baseline, active""]",1.6020599913279625,1.6020599913279625,0.5653073023249671,20,cytokine
BSK_SAg_MCP1_down,"Data from the assay component BSK_SAg_MCP1 was analyzed into 2 assay endpoints. This assay endpoint, BSK_SAg_MCP1_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene CCL2. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cytokine"" intended target family, where the subfamily is ""chemotactic factor"".",NP_002973.1, , , ,,,Active,0.31253291984366305,3.2830724246523495,40.000000000000014,1.6020599913279625,0.031731751991099996,0.22193287,log10_fold_induction,1.60205999132796,0.09519525597329999,"[""Less than 50% efficacy"",""Only one conc above baseline, active""]",1.6020599913279625,1.6020599913279625,1.0380628809777224,20,cytokine
BSK_SAg_PBMCCytotoxicity_down,"Data from the assay component BSK_SAg_PBMCCytotoxicity was analyzed into 2 assay endpoints. This assay endpoint, BSK_SAg_PBMCCytotoxicity_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of viability reporter, loss-of-signal activity can be used to understand changes in the signaling. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cell cycle"" intended target family, where the subfamily is ""proliferation"".",, , , ,,,Active,0.599304757086927,7.568771483167437,40.000000000000014,1.6020599913279625,0.0217234984974,0.49761537,log10_fold_induction,1.60205999132796,0.07918124604762482,"[""Less than 50% efficacy"",""Only one conc above baseline, active""]",1.6020599913279625,1.6020599913279625,1.1945843414772641,20,cell cycle
BSK_SAg_Proliferation_down,"Data from the assay component BSK_SAg_Proliferation was analyzed into 2 assay endpoints. 
This assay endpoint, BSK_SAg_Proliferation_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of viability reporter, measures of total protein for loss-of-signal activity can be used to understand the viability at the cellular-level. 
Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cell cycle"" intended target family, where the subfamily is ""cytotoxicity"".",, , , ,,,Active,1.124418959788933,9.395231519045742,40.000000000000014,1.6020599913279625,0.0398932500141,0.9098343,log10_fold_induction,1.60205999132796,0.1196797500423,"[""Only one conc above baseline, active""]",1.6020599913279625,1.6020599913279625,1.1748558408175438,20,cell cycle
CCTE_Mundy_HCI_Cortical_NOG_BPCount_loss,"Data from the CCTE_Mundy_HCI_Cortical_NOG_BPCount was analyzed at the endpoint CCTE_Mundy_HCI_Cortical_NOG_BPCount_loss in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of morphology reporter, loss -of-signal activity can be used to understand developmental effects.",, , , ,,,Active,96.67019378663272,3.2223397928877575,29.688220326186094,1.4725841643969035,7.341623108665738,99.99997596153845,percent_activity,2,30,,1.4292328060647141,1.4063229285125605,1.3533037117982774,100,neurodevelopment
CCTE_Mundy_HCI_Cortical_NOG_BPCount_loss,"Data from the CCTE_Mundy_HCI_Cortical_NOG_BPCount was analyzed at the endpoint CCTE_Mundy_HCI_Cortical_NOG_BPCount_loss in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of morphology reporter, loss -of-signal activity can be used to understand developmental effects.",, , , ,,,Active,96.67019378663272,3.2223397928877575,29.688220326186094,1.4725841643969035,7.341623108665738,99.99997596153845,percent_activity,2,30,,1.4292328060647141,1.4063229285125605,1.3533037117982774,100,neurodevelopment
CCTE_Mundy_HCI_Cortical_NOG_NeuriteCount_loss,"Data from the CCTE_Mundy_HCI_Cortical_NOG_NeuriteCount was analyzed at the endpoint CCTE_Mundy_HCI_Cortical_NOG_NeuriteCount_loss in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of morphology reporter, loss -of-signal activity can be used to understand developmental effects.",, , , ,,,Active,97.14098409030643,3.2380328030102143,33.170963043582184,1.5207580804565377,3.8015384615384282,99.99996610169491,percent_activity,2,30,,1.4770247486892236,1.4112474606108196,1.40147769640383,100,neurodevelopment
CCTE_Mundy_HCI_Cortical_NOG_NeuriteCount_loss,"Data from the CCTE_Mundy_HCI_Cortical_NOG_NeuriteCount was analyzed at the endpoint CCTE_Mundy_HCI_Cortical_NOG_NeuriteCount_loss in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of morphology reporter, loss -of-signal activity can be used to understand developmental effects.",, , , ,,,Active,97.14098409030643,3.2380328030102143,33.170963043582184,1.5207580804565377,3.8015384615384282,99.99996610169491,percent_activity,2,30,,1.4770247486892236,1.4112474606108196,1.40147769640383,100,neurodevelopment
CCTE_Mundy_HCI_Cortical_NOG_NeuriteLength_loss,"Data from the CCTE_Mundy_HCI_Cortical_NOG_NeuriteLength was analyzed at the endpoint CCTE_Mundy_HCI_Cortical_NOG_NeuriteLength_loss in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of morphology reporter, loss -of-signal activity can be used to understand developmental effects.",, , , ,,,Active,97.2864165333016,3.2428805511100536,32.64594335713692,1.513829222760656,7.094741702808024,99.9999993154436,percent_activity,2,30,,1.4699784242265186,1.4447331409387032,1.3945488263690986,100,neurodevelopment
CCTE_Mundy_HCI_Cortical_NOG_NeuriteLength_loss,"Data from the CCTE_Mundy_HCI_Cortical_NOG_NeuriteLength was analyzed at the endpoint CCTE_Mundy_HCI_Cortical_NOG_NeuriteLength_loss in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of morphology reporter, loss -of-signal activity can be used to understand developmental effects.",, , , ,,,Active,97.2864165333016,3.2428805511100536,32.64594335713692,1.513829222760656,7.094741702808024,99.9999993154436,percent_activity,2,30,,1.4699784242265186,1.4447331409387032,1.3945488263690986,100,neurodevelopment
CCTE_Mundy_HCI_Cortical_NOG_NeuronCount_loss,"Data from the CCTE_Mundy_HCI_Cortical_NOG_NeuronCount was analyzed at the endpoint CCTE_Mundy_HCI_Cortical_NOG_NeuronCount_loss in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of morphology reporter, loss -of-signal activity can be used to understand developmental effects.",, , , ,,,Active,74.54099914663618,2.4846999715545395,42.0433847499373,1.6236976721289849,8.116887316371168,73.56188262638,percent activity,2,30,"[""Only highest conc above baseline, active""]",1.6022421381995646,1.584432729936025,1.5044134867261372,20,neurodevelopment
CCTE_Mundy_HCI_Cortical_NOG_NeuronCount_loss,"Data from the CCTE_Mundy_HCI_Cortical_NOG_NeuronCount was analyzed at the endpoint CCTE_Mundy_HCI_Cortical_NOG_NeuronCount_loss in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of morphology reporter, loss -of-signal activity can be used to understand developmental effects.",, , , ,,,Active,74.54099914663618,2.4846999715545395,42.0433847499373,1.6236976721289849,8.116887316371168,73.56188262638,percent activity,2,30,"[""Only highest conc above baseline, active""]",1.6022421381995646,1.584432729936025,1.5044134867261372,20,neurodevelopment
CCTE_Mundy_HCI_Cortical_Synap&Neur_Matur_BPCount_loss,"Data from the CCTE_Mundy_HCI_Cortical_Synap&Neur_Matur_BPCount was analyzed at the endpoint CCTE_Mundy_HCI_Cortical_Synap&Neur_Matur_BPCount_loss in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of morphology reporter, loss -of-signal activity can be used to understand developmental effects.",, , , ,,,Active,88.82318602427227,2.9607728674757423,26.7490163734687,1.4273078165842008,7.346711411798393,88.68217054263566,percent_activity,2,30,,1.331586432418591,1.2697122155079907,1.1149518314402806,100,neurodevelopment
CCTE_Mundy_HCI_Cortical_Synap&Neur_Matur_BPCount_loss,"Data from the CCTE_Mundy_HCI_Cortical_Synap&Neur_Matur_BPCount was analyzed at the endpoint CCTE_Mundy_HCI_Cortical_Synap&Neur_Matur_BPCount_loss in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of morphology reporter, loss -of-signal activity can be used to understand developmental effects.",, , , ,,,Active,88.82318602427227,2.9607728674757423,26.7490163734687,1.4273078165842008,7.346711411798393,88.68217054263566,percent_activity,2,30,,1.331586432418591,1.2697122155079907,1.1149518314402806,100,neurodevelopment
CCTE_Mundy_HCI_Cortical_Synap&Neur_Matur_CellBodySpotCount_loss,"Data from the CCTE_Mundy_HCI_Cortical_Synap&Neur_Matur_CellBodySpotCount was analyzed at the endpoint CCTE_Mundy_HCI_Cortical_Synap&Neur_Matur_CellBodySpotCount_loss in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of morphology reporter, loss -of-signal activity can be used to understand developmental effects.",, , , ,,,Active,100.56750726374801,2.7086597622589865,92.60657978309511,1.9666418448025786,12.376047700170364,61.11250498710551,percent_activity,2,37.128143100511096,"[""Only highest conc above baseline, active""]",1.9375598813759902,1.9375598813759902,1.8473614720649203,20,neurodevelopment
CCTE_Mundy_HCI_Cortical_Synap&Neur_Matur_CellBodySpotCount_loss,"Data from the CCTE_Mundy_HCI_Cortical_Synap&Neur_Matur_CellBodySpotCount was analyzed at the endpoint CCTE_Mundy_HCI_Cortical_Synap&Neur_Matur_CellBodySpotCount_loss in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of morphology reporter, loss -of-signal activity can be used to understand developmental effects.",, , , ,,,Active,100.56750726374801,2.7086597622589865,92.60657978309511,1.9666418448025786,12.376047700170364,61.11250498710551,percent_activity,2,37.128143100511096,"[""Only highest conc above baseline, active""]",1.9375598813759902,1.9375598813759902,1.8473614720649203,20,neurodevelopment
CCTE_Mundy_HCI_Cortical_Synap&Neur_Matur_NeuriteCount_loss,"Data from the CCTE_Mundy_HCI_Cortical_Synap&Neur_Matur_NeuriteCount was analyzed at the endpoint CCTE_Mundy_HCI_Cortical_Synap&Neur_Matur_NeuriteCount_loss in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of morphology reporter, loss -of-signal activity can be used to understand developmental effects.",, , , ,,,Active,43.959700681753745,1.4653233560584582,29.96607893424703,1.476629919167633,2.6751006706553833,45.689655172413794,percent_activity,2,30,"[""Less than 50% efficacy""]",1.5181605749102722,1.3952487706556993,1.3573495704329392,100,neurodevelopment
CCTE_Mundy_HCI_Cortical_Synap&Neur_Matur_NeuriteCount_loss,"Data from the CCTE_Mundy_HCI_Cortical_Synap&Neur_Matur_NeuriteCount was analyzed at the endpoint CCTE_Mundy_HCI_Cortical_Synap&Neur_Matur_NeuriteCount_loss in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of morphology reporter, loss -of-signal activity can be used to understand developmental effects.",, , , ,,,Active,43.959700681753745,1.4653233560584582,29.96607893424703,1.476629919167633,2.6751006706553833,45.689655172413794,percent_activity,2,30,"[""Less than 50% efficacy""]",1.5181605749102722,1.3952487706556993,1.3573495704329392,100,neurodevelopment
CCTE_Mundy_HCI_Cortical_Synap&Neur_Matur_NeuriteLength_loss,"Data from the CCTE_Mundy_HCI_Cortical_Synap&Neur_Matur_NeuriteLength was analyzed at the endpoint CCTE_Mundy_HCI_Cortical_Synap&Neur_Matur_NeuriteLength_loss in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of morphology reporter, loss -of-signal activity can be used to understand developmental effects.",, , , ,,,Active,93.66784783785201,3.122261594595067,31.22320065823685,1.4944774200897268,7.809103377083028,90.46211801383431,percent activity,2,30,,1.372433164059513,1.3163902833283558,1.1381120473508786,100,neurodevelopment
CCTE_Mundy_HCI_Cortical_Synap&Neur_Matur_NeuriteLength_loss,"Data from the CCTE_Mundy_HCI_Cortical_Synap&Neur_Matur_NeuriteLength was analyzed at the endpoint CCTE_Mundy_HCI_Cortical_Synap&Neur_Matur_NeuriteLength_loss in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of morphology reporter, loss -of-signal activity can be used to understand developmental effects.",, , , ,,,Active,93.66784783785201,3.122261594595067,31.22320065823685,1.4944774200897268,7.809103377083028,90.46211801383431,percent activity,2,30,,1.372433164059513,1.3163902833283558,1.1381120473508786,100,neurodevelopment
CCTE_Mundy_HCI_Cortical_Synap&Neur_Matur_NeuriteSpotCountPerNeuriteLength_loss,"Data from the CCTE_Mundy_HCI_Cortical_Synap&Neur_Matur_NeuriteSpotCountPerNeuriteLength was analyzed at the endpoint CCTE_Mundy_HCI_Cortical_Synap&Neur_Matur_NeuriteSpotCountPerNeuriteLength_loss in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of morphology reporter, loss -of-signal activity can be used to understand developmental effects.",, , , ,,,Active,62.279268873369034,2.075975629112301,50.58401693139167,1.7040133141714584,9.266250000000007,47.75143090760425,percent activity,2,30,"[""Less than 50% efficacy"",""Only highest conc above baseline, active""]",1.6867168879307457,1.653134971813343,1.1850283572352958,20,neurodevelopment
CCTE_Mundy_HCI_Cortical_Synap&Neur_Matur_NeuriteSpotCountPerNeuriteLength_loss,"Data from the CCTE_Mundy_HCI_Cortical_Synap&Neur_Matur_NeuriteSpotCountPerNeuriteLength was analyzed at the endpoint CCTE_Mundy_HCI_Cortical_Synap&Neur_Matur_NeuriteSpotCountPerNeuriteLength_loss in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of morphology reporter, loss -of-signal activity can be used to understand developmental effects.",, , , ,,,Active,62.279268873369034,2.075975629112301,50.58401693139167,1.7040133141714584,9.266250000000007,47.75143090760425,percent activity,2,30,"[""Less than 50% efficacy"",""Only highest conc above baseline, active""]",1.6867168879307457,1.653134971813343,1.1850283572352958,20,neurodevelopment
CCTE_Mundy_HCI_Cortical_Synap&Neur_Matur_NeuriteSpotCountPerNeuron_loss,"Data from the CCTE_Mundy_HCI_Cortical_Synap&Neur_Matur_NeuriteSpotCountPerNeuron was analyzed at the endpoint CCTE_Mundy_HCI_Cortical_Synap&Neur_Matur_NeuriteSpotCountPerNeuron_loss in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of morphology reporter, loss -of-signal activity can be used to understand developmental effects.",, , , ,,,Active,84.2677567904556,2.4750015109501264,29.696345795461184,1.4727030116571105,11.349185905224777,87.10276516714816,percent activity,2,34.04755771567433,,1.451603740858561,1.451603740858561,1.3534214957963806,100,neurodevelopment
CCTE_Mundy_HCI_Cortical_Synap&Neur_Matur_NeuriteSpotCountPerNeuron_loss,"Data from the CCTE_Mundy_HCI_Cortical_Synap&Neur_Matur_NeuriteSpotCountPerNeuron was analyzed at the endpoint CCTE_Mundy_HCI_Cortical_Synap&Neur_Matur_NeuriteSpotCountPerNeuron_loss in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of morphology reporter, loss -of-signal activity can be used to understand developmental effects.",, , , ,,,Active,84.2677567904556,2.4750015109501264,29.696345795461184,1.4727030116571105,11.349185905224777,87.10276516714816,percent activity,2,34.04755771567433,,1.451603740858561,1.451603740858561,1.3534214957963806,100,neurodevelopment
CCTE_Mundy_HCI_Cortical_Synap&Neur_Matur_NeuronCount_loss,"Data from the CCTE_Mundy_HCI_Cortical_Synap&Neur_Matur_NeuronCount was analyzed at the endpoint CCTE_Mundy_HCI_Cortical_Synap&Neur_Matur_NeuronCount_loss in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of morphology reporter, loss -of-signal activity can be used to understand developmental effects.",, , , ,,,Active,84.59754629788873,2.8199182099296243,24.549789438047675,1.3900477715593476,6.844875346260387,86.91944367825243,percent_activity,2,30,,1.3575412849669335,1.3282827745906063,1.2707674476909316,20,neurodevelopment
CCTE_Mundy_HCI_Cortical_Synap&Neur_Matur_NeuronCount_loss,"Data from the CCTE_Mundy_HCI_Cortical_Synap&Neur_Matur_NeuronCount was analyzed at the endpoint CCTE_Mundy_HCI_Cortical_Synap&Neur_Matur_NeuronCount_loss in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of morphology reporter, loss -of-signal activity can be used to understand developmental effects.",, , , ,,,Active,84.59754629788873,2.8199182099296243,24.549789438047675,1.3900477715593476,6.844875346260387,86.91944367825243,percent_activity,2,30,,1.3575412849669335,1.3282827745906063,1.2707674476909316,20,neurodevelopment
CCTE_Mundy_HCI_Cortical_Synap&Neur_Matur_SynapseCount_loss,"Data from the CCTE_Mundy_HCI_Cortical_Synap&Neur_Matur_SynapseCount was analyzed at the endpoint CCTE_Mundy_HCI_Cortical_Synap&Neur_Matur_SynapseCount_loss in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of morphology reporter, loss -of-signal activity can be used to understand developmental effects.",, , , ,,,Active,68.52570250227723,2.0809400451073663,29.32695238518391,1.4672669340659064,10.976722221189164,69.49635166399715,percent activity,2,32.93016666356749,,1.463041730009089,1.463041730009089,1.347986527934558,100,neurodevelopment
CCTE_Mundy_HCI_Cortical_Synap&Neur_Matur_SynapseCount_loss,"Data from the CCTE_Mundy_HCI_Cortical_Synap&Neur_Matur_SynapseCount was analyzed at the endpoint CCTE_Mundy_HCI_Cortical_Synap&Neur_Matur_SynapseCount_loss in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of morphology reporter, loss -of-signal activity can be used to understand developmental effects.",, , , ,,,Active,68.52570250227723,2.0809400451073663,29.32695238518391,1.4672669340659064,10.976722221189164,69.49635166399715,percent activity,2,32.93016666356749,,1.463041730009089,1.463041730009089,1.347986527934558,100,neurodevelopment
CCTE_Mundy_HCI_hN2_NOG_BPCount_loss,"Data from the CCTE_Mundy_HCI_hN2_NOG_BPCount was analyzed at the endpoint CCTE_Mundy_HCI_hN2_NOG_BPCount_loss in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of morphology reporter, loss -of-signal activity can be used to understand developmental effects.",, , , ,,,Active,92.51620631741282,2.453747066609937,27.083301603770316,1.4327016061319067,12.568017241379316,91.83673469387756,percent_activity,2,37.70405172413795,,1.4123904992778176,1.4123904992778176,1.3134212899410787,20,neurodevelopment
CCTE_Mundy_HCI_hN2_NOG_BPCount_loss,"Data from the CCTE_Mundy_HCI_hN2_NOG_BPCount was analyzed at the endpoint CCTE_Mundy_HCI_hN2_NOG_BPCount_loss in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of morphology reporter, loss -of-signal activity can be used to understand developmental effects.",, , , ,,,Active,92.51620631741282,2.453747066609937,27.083301603770316,1.4327016061319067,12.568017241379316,91.83673469387756,percent_activity,2,37.70405172413795,,1.4123904992778176,1.4123904992778176,1.3134212899410787,20,neurodevelopment
CCTE_Mundy_HCI_hN2_NOG_NeuriteCount_loss,"Data from the CCTE_Mundy_HCI_hN2_NOG_NeuriteCount was analyzed at the endpoint CCTE_Mundy_HCI_hN2_NOG_NeuriteCount_loss in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of morphology reporter, loss -of-signal activity can be used to understand developmental effects.",, , , ,,,Active,84.44196253925824,2.8147320846419412,28.95850794755677,1.4617761815984527,3.530500354358604,85.0828729281768,percent activity,2,30,,1.4294246054948399,1.3563516820470212,1.342495825902922,20,neurodevelopment
CCTE_Mundy_HCI_hN2_NOG_NeuriteCount_loss,"Data from the CCTE_Mundy_HCI_hN2_NOG_NeuriteCount was analyzed at the endpoint CCTE_Mundy_HCI_hN2_NOG_NeuriteCount_loss in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of morphology reporter, loss -of-signal activity can be used to understand developmental effects.",, , , ,,,Active,84.44196253925824,2.8147320846419412,28.95850794755677,1.4617761815984527,3.530500354358604,85.0828729281768,percent activity,2,30,,1.4294246054948399,1.3563516820470212,1.342495825902922,20,neurodevelopment
CCTE_Mundy_HCI_hN2_NOG_NeuriteLength_loss,"Data from the CCTE_Mundy_HCI_hN2_NOG_NeuriteLength was analyzed at the endpoint CCTE_Mundy_HCI_hN2_NOG_NeuriteLength_loss in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of morphology reporter, loss -of-signal activity can be used to understand developmental effects.",, , , ,,,Active,88.89685325257643,2.963228441752548,27.895610113158977,1.4455358644336314,6.958050541516249,89.82203803022917,percent_activity,2,30,,1.408914505208063,1.3814052260515643,1.326255535832153,20,neurodevelopment
CCTE_Mundy_HCI_hN2_NOG_NeuriteLength_loss,"Data from the CCTE_Mundy_HCI_hN2_NOG_NeuriteLength was analyzed at the endpoint CCTE_Mundy_HCI_hN2_NOG_NeuriteLength_loss in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of morphology reporter, loss -of-signal activity can be used to understand developmental effects.",, , , ,,,Active,88.89685325257643,2.963228441752548,27.895610113158977,1.4455358644336314,6.958050541516249,89.82203803022917,percent_activity,2,30,,1.408914505208063,1.3814052260515643,1.326255535832153,20,neurodevelopment
CCTE_Mundy_HCI_hN2_NOG_NeuronCount_loss,"Data from the CCTE_Mundy_HCI_hN2_NOG_NeuronCount was analyzed at the endpoint CCTE_Mundy_HCI_hN2_NOG_NeuronCount_loss in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of morphology reporter, loss -of-signal activity can be used to understand developmental effects.",, , , ,,,Active,85.18942732252526,2.6251096465600146,20.49397007958708,1.3116260978176268,10.817253218884126,87.1410201457351,percent_activity,2,32.45175965665238,"[""Noisy data""]",1.2612902330741358,1.2612902330741358,1.083856683273387,20,neurodevelopment
CCTE_Mundy_HCI_hN2_NOG_NeuronCount_loss,"Data from the CCTE_Mundy_HCI_hN2_NOG_NeuronCount was analyzed at the endpoint CCTE_Mundy_HCI_hN2_NOG_NeuronCount_loss in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of morphology reporter, loss -of-signal activity can be used to understand developmental effects.",, , , ,,,Active,85.18942732252526,2.6251096465600146,20.49397007958708,1.3116260978176268,10.817253218884126,87.1410201457351,percent_activity,2,32.45175965665238,"[""Noisy data""]",1.2612902330741358,1.2612902330741358,1.083856683273387,20,neurodevelopment
CCTE_Mundy_HCI_hNP1_Casp3_7_gain,"Data from the CCTE_Mundy_HCI_hNP1_Casp3_7 was analyzed at the endpoint CCTE_Mundy_HCI_hNP1_Casp3_7_gain in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of viability reporter, gain -of-signal activity can be used to understand viability effects.",, , , ,,,Active,72.12125916504694,2.404041972168231,12.161461766145287,1.0849857787867643,4.584589533952789,64.87189281306928,percent_activity,2,30,,0.5937188098067472,-1.0075119157754455,-2.095822585754423,100,cell cycle
CCTE_Mundy_HCI_hNP1_Casp3_7_gain,"Data from the CCTE_Mundy_HCI_hNP1_Casp3_7 was analyzed at the endpoint CCTE_Mundy_HCI_hNP1_Casp3_7_gain in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of viability reporter, gain -of-signal activity can be used to understand viability effects.",, , , ,,,Active,72.12125916504694,2.404041972168231,12.161461766145287,1.0849857787867643,4.584589533952789,64.87189281306928,percent_activity,2,30,,0.5937188098067472,-1.0075119157754455,-2.095822585754423,100,cell cycle
CCTE_Mundy_HCI_hNP1_CellTiter_loss,"Data from the CCTE_Mundy_HCI_hNP1_CellTiter was analyzed at the endpoint CCTE_Mundy_HCI_hNP1_CellTiter_loss in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of viability reporter, loss -of-signal activity can be used to understand viability effects.",, , , ,,,Active,72.89744993533144,2.429914997844381,35.47541830397008,1.549927525088917,4.959125146974272,71.20191246365546,percent_activity,2,30,,1.5145244810359388,1.4151969299660914,1.3324074590670683,100,cell cycle
CCTE_Mundy_HCI_hNP1_CellTiter_loss,"Data from the CCTE_Mundy_HCI_hNP1_CellTiter was analyzed at the endpoint CCTE_Mundy_HCI_hNP1_CellTiter_loss in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of viability reporter, loss -of-signal activity can be used to understand viability effects.",, , , ,,,Active,72.89744993533144,2.429914997844381,35.47541830397008,1.549927525088917,4.959125146974272,71.20191246365546,percent_activity,2,30,,1.5145244810359388,1.4151969299660914,1.3324074590670683,100,cell cycle
CCTE_Mundy_HCI_hNP1_Pro_MeanAvgInten_loss,"Data from the CCTE_Mundy_HCI_hNP1_Pro_MeanAvgInten was analyzed at the endpoint CCTE_Mundy_HCI_hNP1_Pro_MeanAvgInten_loss in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of growth reporter, loss -of-signal activity can be used to understand viability effects.",, , , ,,,Active,76.18422023140437,1.3856931657637739,17.78636001994813,1.2500870787754632,18.32638040264677,79.08761160714286,percent_activity,2,54.97914120794031,,1.33372885358745,1.33372885358745,1.0571856093313206,100,cell cycle
CCTE_Mundy_HCI_hNP1_Pro_MeanAvgInten_loss,"Data from the CCTE_Mundy_HCI_hNP1_Pro_MeanAvgInten was analyzed at the endpoint CCTE_Mundy_HCI_hNP1_Pro_MeanAvgInten_loss in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of growth reporter, loss -of-signal activity can be used to understand viability effects.",, , , ,,,Active,76.18422023140437,1.3856931657637739,17.78636001994813,1.2500870787754632,18.32638040264677,79.08761160714286,percent_activity,2,54.97914120794031,,1.33372885358745,1.33372885358745,1.0571856093313206,100,cell cycle
CCTE_Mundy_HCI_hNP1_Pro_ObjectCount_loss,"Data from the CCTE_Mundy_HCI_hNP1_Pro_ObjectCount was analyzed at the endpoint CCTE_Mundy_HCI_hNP1_Pro_ObjectCount_loss in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of growth reporter, loss -of-signal activity can be used to understand viability effects.",, , , ,,,Active,88.4777121395185,1.09279393445983,32.35112515962628,1.509889389861576,26.988226950354612,89.20835729346366,percent activity,2,80.96468085106383,"[""Only highest conc above baseline, active"",""Borderline active""]",1.6389494698656533,1.6389494698656533,1.3906090497005952,100,cell cycle
CCTE_Mundy_HCI_hNP1_Pro_ObjectCount_loss,"Data from the CCTE_Mundy_HCI_hNP1_Pro_ObjectCount was analyzed at the endpoint CCTE_Mundy_HCI_hNP1_Pro_ObjectCount_loss in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of growth reporter, loss -of-signal activity can be used to understand viability effects.",, , , ,,,Active,88.4777121395185,1.09279393445983,32.35112515962628,1.509889389861576,26.988226950354612,89.20835729346366,percent activity,2,80.96468085106383,"[""Only highest conc above baseline, active"",""Borderline active""]",1.6389494698656533,1.6389494698656533,1.3906090497005952,100,cell cycle
CCTE_Mundy_HCI_hNP1_Pro_ResponderAvgInten_loss,"Data from the CCTE_Mundy_HCI_hNP1_Pro_ResponderAvgInten was analyzed at the endpoint CCTE_Mundy_HCI_hNP1_Pro_ResponderAvgInten_loss in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of growth reporter, loss -of-signal activity can be used to understand viability effects.",, , , ,,,Active,89.43035098108656,2.592107104431758,19.79325684268211,1.2965172602211348,11.500341534008681,91.92139737991268,percent activity,2,34.50102460202604,,1.2712707251834687,1.2712707251834687,1.1772369465392902,100,cell cycle
CCTE_Mundy_HCI_hNP1_Pro_ResponderAvgInten_loss,"Data from the CCTE_Mundy_HCI_hNP1_Pro_ResponderAvgInten was analyzed at the endpoint CCTE_Mundy_HCI_hNP1_Pro_ResponderAvgInten_loss in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of growth reporter, loss -of-signal activity can be used to understand viability effects.",, , , ,,,Active,89.43035098108656,2.592107104431758,19.79325684268211,1.2965172602211348,11.500341534008681,91.92139737991268,percent activity,2,34.50102460202604,,1.2712707251834687,1.2712707251834687,1.1772369465392902,100,cell cycle
CCTE_Padilla_ZF_144hpf_TERATOSCORE_up,"Data from the assay component CCTE_Padilla_ZF_144hpf_TERATOSCORE was analyzed into 1 assay endpoint. This assay endpoint, CCTE_Padilla_ZF_144hpf_TERATOSCORE_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of morphological reporter, gain-of-signal activity can be used to understand changes in  developmental defect  as they relate to the whole embryo. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""malformation"" intended target family, where the subfamily is ""total"".",, , , ,,,Active,98.8789138319803,4.943945691599015,4.239350751460155,0.627299350307746,1.53481347591287,98.9416597195868,percent_activity,0.903089986991944,20,"[""Noisy data"",""Noisy data""]",0.552807984086905,0.463397192187447,0.508019035883043,20,malformation
CCTE_Shafer_MEA_dev_AB_dn,"Data from the CCTE_Shafer_MEA_dev_AB was analyzed at the assay endpoint CCTE_Shafer_MEA_dev_AB_dn in the negative analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of functional reporter, loss-of-signal activity can be used to understand cell viability.",, , , ,,,Active,99.0368039956876,5.077356442741609,14.309296439162235,1.15561828085264,6.50186142549743,99.1675057792401,percent activity,1.47712125471966,19.5055842764923,,1.07932087985062,1.07932087985062,1.03633786382377,100,cell cycle
CCTE_Shafer_MEA_dev_AB_dn,"Data from the CCTE_Shafer_MEA_dev_AB was analyzed at the assay endpoint CCTE_Shafer_MEA_dev_AB_dn in the negative analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of functional reporter, loss-of-signal activity can be used to understand cell viability.",, , , ,,,Active,99.0368039956876,5.077356442741609,14.309296439162235,1.15561828085264,6.50186142549743,99.1675057792401,percent activity,1.47712125471966,19.5055842764923,,1.07932087985062,1.07932087985062,1.03633786382377,100,cell cycle
CCTE_Shafer_MEA_dev_active_electrodes_number_dn,"Data from the CCTE_Shafer_MEA_dev_active_electrodes_number was analyzed at the assay endpoint CCTE_Shafer_MEA_dev_active_electrodes_number_dn in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of functional reporter, loss-of-signal activity can be used to understand electrical activity.",, , , ,,,Active,100.732038952959,3.8047984495924076,17.7440832608408,1.24905356665669,8.825,100,percent activity,1.47712125471966,26.475,,1.19306585931725,1.19306585931725,1.12977325296863,100,neurodevelopment
CCTE_Shafer_MEA_dev_active_electrodes_number_dn,"Data from the CCTE_Shafer_MEA_dev_active_electrodes_number was analyzed at the assay endpoint CCTE_Shafer_MEA_dev_active_electrodes_number_dn in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of functional reporter, loss-of-signal activity can be used to understand electrical activity.",, , , ,,,Active,100.732038952959,3.8047984495924076,17.7440832608408,1.24905356665669,8.825,100,percent activity,1.47712125471966,26.475,,1.19306585931725,1.19306585931725,1.12977325296863,100,neurodevelopment
CCTE_Shafer_MEA_dev_burst_duration_mean_dn,"Data from the assay component CCTE_Shafer_MEA_dev_burst_duration_mean was analyzed into 2 assay endpoints. This assay endpoint, CCTE_Shafer_MEA_dev_burst_duration_mean_dn, was analyzed in the negative analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of functional reporter, loss-of-signal activity can be used to understand electrical activity.",, , , ,,,Active,101.151796521661,1.3985885726315197,16.35387162488058,1.21362058429142,24.1080659223316,100,percent_activity,1.47712125471966,72.3241977669948,"[""Only highest conc above baseline, active""]",1.2679018819302,1.2679018819302,1.08395664691821,20,neurodevelopment
CCTE_Shafer_MEA_dev_burst_duration_mean_dn,"Data from the assay component CCTE_Shafer_MEA_dev_burst_duration_mean was analyzed into 2 assay endpoints. This assay endpoint, CCTE_Shafer_MEA_dev_burst_duration_mean_dn, was analyzed in the negative analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of functional reporter, loss-of-signal activity can be used to understand electrical activity.",, , , ,,,Active,101.151796521661,1.3985885726315197,16.35387162488058,1.21362058429142,24.1080659223316,100,percent_activity,1.47712125471966,72.3241977669948,"[""Only highest conc above baseline, active""]",1.2679018819302,1.2679018819302,1.08395664691821,20,neurodevelopment
CCTE_Shafer_MEA_dev_bursting_electrodes_number_dn,"Data from the CCTE_Shafer_MEA_dev_bursting_electrodes_number was analyzed at the assay endpoint CCTE_Shafer_MEA_dev_bursting_electrodes_number_dn in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of functional reporter, loss-of-signal activity can be used to understand electrical activity.",, , , ,,,Active,101.379672239067,2.6440132154619795,19.21810111959093,1.28371047417416,12.7810344827586,100,percent activity,1.47712125471966,38.3431034482758,,1.25672231108919,1.25672231108919,1.16443016029028,100,neurodevelopment
CCTE_Shafer_MEA_dev_bursting_electrodes_number_dn,"Data from the CCTE_Shafer_MEA_dev_bursting_electrodes_number was analyzed at the assay endpoint CCTE_Shafer_MEA_dev_bursting_electrodes_number_dn in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of functional reporter, loss-of-signal activity can be used to understand electrical activity.",, , , ,,,Active,101.379672239067,2.6440132154619795,19.21810111959093,1.28371047417416,12.7810344827586,100,percent activity,1.47712125471966,38.3431034482758,,1.25672231108919,1.25672231108919,1.16443016029028,100,neurodevelopment
CCTE_Shafer_MEA_dev_burst_rate_dn,"Data from the CCTE_Shafer_MEA_dev_burst_rate was analyzed at the assay endpoint CCTE_Shafer_MEA_dev_burst_rate_dn in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of functional reporter, loss-of-signal activity can be used to understand electrical activity.",, , , ,,,Active,100.072161388805,1.3662233329447426,13.14346421311867,1.11870984698599,24.4157644839102,100,percent activity,1.47712125471966,73.2472934517306,,1.17379860291148,1.17379860291148,0.99821116045642,100,neurodevelopment
CCTE_Shafer_MEA_dev_burst_rate_dn,"Data from the CCTE_Shafer_MEA_dev_burst_rate was analyzed at the assay endpoint CCTE_Shafer_MEA_dev_burst_rate_dn in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of functional reporter, loss-of-signal activity can be used to understand electrical activity.",, , , ,,,Active,100.072161388805,1.3662233329447426,13.14346421311867,1.11870984698599,24.4157644839102,100,percent activity,1.47712125471966,73.2472934517306,,1.17379860291148,1.17379860291148,0.99821116045642,100,neurodevelopment
CCTE_Shafer_MEA_dev_correlation_coefficient_mean_dn,"Data from the assay component CCTE_Shafer_MEA_dev_correlation_coefficient_mean was analyzed into 2 assay endpoints. This assay endpoint, CCTE_Shafer_MEA_dev_correlation_coefficient_mean_dn, was analyzed in the negative analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of functional reporter, loss-of-signal activity can be used to understand electrical activity.",, , , ,,,Active,101.911224610707,1.9983527238350234,20.102018845840607,1.30323967580754,16.9992052946372,100,percent_activity,1.47712125471966,50.9976158839116,,1.30332917491345,1.30332917491345,1.18395935918467,100,neurodevelopment
CCTE_Shafer_MEA_dev_correlation_coefficient_mean_dn,"Data from the assay component CCTE_Shafer_MEA_dev_correlation_coefficient_mean was analyzed into 2 assay endpoints. This assay endpoint, CCTE_Shafer_MEA_dev_correlation_coefficient_mean_dn, was analyzed in the negative analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of functional reporter, loss-of-signal activity can be used to understand electrical activity.",, , , ,,,Active,101.911224610707,1.9983527238350234,20.102018845840607,1.30323967580754,16.9992052946372,100,percent_activity,1.47712125471966,50.9976158839116,,1.30332917491345,1.30332917491345,1.18395935918467,100,neurodevelopment
CCTE_Shafer_MEA_dev_firing_rate_mean_dn,"Data from the CCTE_Shafer_MEA_dev_firing_rate_mean was analyzed at the assay endpoint CCTE_Shafer_MEA_dev_firing_rate_mean_dn in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of functional reporter, loss-of-signal activity can be used to understand electrical activity.",, , , ,,,Active,100.33536496658,1.4196022501744707,12.681519968499662,1.10317130988411,23.5595017205814,100,percent activity,1.47712125471966,70.6785051617442,,1.16821272986452,1.16821272986452,0.938612695004548,100,neurodevelopment
CCTE_Shafer_MEA_dev_firing_rate_mean_dn,"Data from the CCTE_Shafer_MEA_dev_firing_rate_mean was analyzed at the assay endpoint CCTE_Shafer_MEA_dev_firing_rate_mean_dn in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of functional reporter, loss-of-signal activity can be used to understand electrical activity.",, , , ,,,Active,100.33536496658,1.4196022501744707,12.681519968499662,1.10317130988411,23.5595017205814,100,percent activity,1.47712125471966,70.6785051617442,,1.16821272986452,1.16821272986452,0.938612695004548,100,neurodevelopment
CCTE_Shafer_MEA_dev_interburst_interval_mean_dn,"Data from the CCTE_Shafer_MEA_dev_interburst_interval_mean was analyzed at the assay endpoint CCTE_Shafer_MEA_dev_interburst_interval_mean_dn in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of functional reporter, loss-of-signal activity can be used to understand electrical activity.",, , , ,,,Active,100.294630613036,1.5513963223379246,15.807406207229812,1.19886061361963,21.5493249895668,100,percent activity,1.47712125471966,64.6479749687004,,1.23117763509998,1.23117763509998,1.07958028287037,100,neurodevelopment
CCTE_Shafer_MEA_dev_interburst_interval_mean_dn,"Data from the CCTE_Shafer_MEA_dev_interburst_interval_mean was analyzed at the assay endpoint CCTE_Shafer_MEA_dev_interburst_interval_mean_dn in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of functional reporter, loss-of-signal activity can be used to understand electrical activity.",, , , ,,,Active,100.294630613036,1.5513963223379246,15.807406207229812,1.19886061361963,21.5493249895668,100,percent activity,1.47712125471966,64.6479749687004,,1.23117763509998,1.23117763509998,1.07958028287037,100,neurodevelopment
CCTE_Shafer_MEA_dev_inter_network_spike_interval_mean_dn,"Data from the assay component CCTE_Shafer_MEA_dev_inter_network_spike_interval_mean was analyzed into 2 assay endpoints. This assay endpoint, CCTE_Shafer_MEA_dev_inter_network_spike_interval_mean_dn, was analyzed in the negative analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of functional reporter, loss-of-signal activity can be used to understand electrical activity.",, , , ,,,Active,100.173227925289,1.175898921520366,12.879470606418376,1.10989801229116,28.3962127730534,100,percent_activity,1.47712125471966,85.1886383191602,"[""Borderline active""]",1.2226703222391,1.2226703222391,0.967315685952095,100,neurodevelopment
CCTE_Shafer_MEA_dev_LDH_dn,"Data from the assay component CCTE_Shafer_MEA_dev_LDH was analyzed into 1 assay endpoint. This assay endpoint, CCTE_Shafer_MEA_dev_LDH_dn, was analyzed in the negative analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of viability reporter, loss-of-signal activity can be used to understand cell viability.",, , , ,,,Active,99.6055042727601,4.168492544423999,13.738272981118133,1.13793214160916,7.96495001580351,99.5639572165081,percent_activity,2,23.8948500474105,,1.07532550801844,1.07532550801844,1.01865173762733,100,cell cycle
CCTE_Shafer_MEA_dev_LDH_dn,"Data from the assay component CCTE_Shafer_MEA_dev_LDH was analyzed into 1 assay endpoint. This assay endpoint, CCTE_Shafer_MEA_dev_LDH_dn, was analyzed in the negative analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of viability reporter, loss-of-signal activity can be used to understand cell viability.",, , , ,,,Active,99.6055042727601,4.168492544423999,13.738272981118133,1.13793214160916,7.96495001580351,99.5639572165081,percent_activity,2,23.8948500474105,,1.07532550801844,1.07532550801844,1.01865173762733,100,cell cycle
CCTE_Shafer_MEA_dev_mutual_information_norm_dn,"Data from the assay component CCTE_Shafer_MEA_dev_mutual_information_norm was analyzed into 2 assay endpoints. This assay endpoint, CCTE_Shafer_MEA_dev_mutual_information_norm_dn, was analyzed in the negative analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of functional reporter, loss-of-signal activity can be used to understand electrical activity.",, , , ,,,Active,101.376244819335,1.4008756651573167,19.24598899782223,1.28434023318903,24.1221133658926,100,percent_activity,1.47712125471966,72.3663400976778,,1.33396402165926,1.33396402165926,1.16505991911647,100,neurodevelopment
CCTE_Shafer_MEA_dev_mutual_information_norm_dn,"Data from the assay component CCTE_Shafer_MEA_dev_mutual_information_norm was analyzed into 2 assay endpoints. This assay endpoint, CCTE_Shafer_MEA_dev_mutual_information_norm_dn, was analyzed in the negative analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of functional reporter, loss-of-signal activity can be used to understand electrical activity.",, , , ,,,Active,101.376244819335,1.4008756651573167,19.24598899782223,1.28434023318903,24.1221133658926,100,percent_activity,1.47712125471966,72.3663400976778,,1.33396402165926,1.33396402165926,1.16505991911647,100,neurodevelopment
CCTE_Shafer_MEA_dev_network_spike_duration_std_dn,"Data from the assay component CCTE_Shafer_MEA_dev_network_spike_duration_std was analyzed into 2 assay endpoints. This assay endpoint, CCTE_Shafer_MEA_dev_network_spike_duration_std_dn, was analyzed in the negative analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of functional reporter, loss-of-signal activity can be used to understand electrical activity.",, , , ,,,Active,100.789575127912,1.3161304487427143,17.914700562536865,1.25320955349433,25.5267440053011,100,percent_activity,1.47712125471966,76.5802320159033,,1.31572626272841,1.31572626272841,1.13392923941444,100,neurodevelopment
CCTE_Shafer_MEA_dev_network_spike_duration_std_dn,"Data from the assay component CCTE_Shafer_MEA_dev_network_spike_duration_std was analyzed into 2 assay endpoints. This assay endpoint, CCTE_Shafer_MEA_dev_network_spike_duration_std_dn, was analyzed in the negative analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of functional reporter, loss-of-signal activity can be used to understand electrical activity.",, , , ,,,Active,100.789575127912,1.3161304487427143,17.914700562536865,1.25320955349433,25.5267440053011,100,percent_activity,1.47712125471966,76.5802320159033,,1.31572626272841,1.31572626272841,1.13392923941444,100,neurodevelopment
CCTE_Shafer_MEA_dev_network_spike_number_dn,"Data from the assay component CCTE_Shafer_MEA_dev_network_spike_number was analyzed into 2 assay endpoints. This assay endpoint, CCTE_Shafer_MEA_dev_network_spike_number_dn, was analyzed in the negative analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of functional reporter, loss-of-signal activity can be used to understand electrical activity.",, , , ,,,Active,101.071211551536,1.2911627007435054,18.630767458402673,1.27023074518526,26.0930739643514,100,percent_activity,1.47712125471966,78.2792218930542,,1.33721377959478,1.33721377959478,1.15095042830076,100,neurodevelopment
CCTE_Shafer_MEA_dev_network_spike_number_dn,"Data from the assay component CCTE_Shafer_MEA_dev_network_spike_number was analyzed into 2 assay endpoints. This assay endpoint, CCTE_Shafer_MEA_dev_network_spike_number_dn, was analyzed in the negative analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of functional reporter, loss-of-signal activity can be used to understand electrical activity.",, , , ,,,Active,101.071211551536,1.2911627007435054,18.630767458402673,1.27023074518526,26.0930739643514,100,percent_activity,1.47712125471966,78.2792218930542,,1.33721377959478,1.33721377959478,1.15095042830076,100,neurodevelopment
CCTE_Shafer_MEA_dev_network_spike_peak_dn,"Data from the CCTE_Shafer_MEA_dev_network_spike_peak was analyzed at the assay endpoint CCTE_Shafer_MEA_dev_network_spike_peak_dn in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of functional reporter, loss-of-signal activity can be used to understand electrical activity.",, , , ,,,Active,101.097649694831,3.729781440777708,18.694193053703025,1.27170672330743,9.03517192629845,100,percent activity,1.47712125471966,27.1055157788953,,1.21719073871114,1.21719073871114,1.15242640962495,100,neurodevelopment
CCTE_Shafer_MEA_dev_network_spike_peak_dn,"Data from the CCTE_Shafer_MEA_dev_network_spike_peak was analyzed at the assay endpoint CCTE_Shafer_MEA_dev_network_spike_peak_dn in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of functional reporter, loss-of-signal activity can be used to understand electrical activity.",, , , ,,,Active,101.097649694831,3.729781440777708,18.694193053703025,1.27170672330743,9.03517192629845,100,percent activity,1.47712125471966,27.1055157788953,,1.21719073871114,1.21719073871114,1.15242640962495,100,neurodevelopment
CCTE_Shafer_MEA_dev_per_burst_interspike_interval_dn,"Data from the CCTE_Shafer_MEA_dev_per_burst_interspike_interval was analyzed at the assay endpoint CCTE_Shafer_MEA_dev_per_burst_interspike_interval_dn in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of functional reporter, loss-of-signal activity can be used to understand electrical activity.",, , , ,,,Active,100.250021533503,1.4457898306681656,12.800856190407155,1.10723901858019,23.1130923289574,100,percent activity,1.47712125471966,69.3392769868722,,1.16372036016011,1.16372036016011,0.953629643978623,100,neurodevelopment
CCTE_Shafer_MEA_dev_per_burst_interspike_interval_dn,"Data from the CCTE_Shafer_MEA_dev_per_burst_interspike_interval was analyzed at the assay endpoint CCTE_Shafer_MEA_dev_per_burst_interspike_interval_dn in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of functional reporter, loss-of-signal activity can be used to understand electrical activity.",, , , ,,,Active,100.250021533503,1.4457898306681656,12.800856190407155,1.10723901858019,23.1130923289574,100,percent activity,1.47712125471966,69.3392769868722,,1.16372036016011,1.16372036016011,0.953629643978623,100,neurodevelopment
CCTE_Shafer_MEA_dev_per_burst_spike_percent_dn,"Data from the CCTE_Shafer_MEA_dev_per_burst_spike_percent was analyzed at the assay endpoint CCTE_Shafer_MEA_dev_per_burst_spike_percent_dn in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of functional reporter, loss-of-signal activity can be used to understand electrical activity.",, , , ,,,Active,101.519522545984,2.99316687857538,19.501455416864776,1.29006702448694,11.305698018671,100,percent activity,1.47712125471966,33.917094056013,,1.25262406676627,1.25262406676627,1.17078671077146,100,neurodevelopment
CCTE_Shafer_MEA_dev_per_burst_spike_percent_dn,"Data from the CCTE_Shafer_MEA_dev_per_burst_spike_percent was analyzed at the assay endpoint CCTE_Shafer_MEA_dev_per_burst_spike_percent_dn in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of functional reporter, loss-of-signal activity can be used to understand electrical activity.",, , , ,,,Active,101.519522545984,2.99316687857538,19.501455416864776,1.29006702448694,11.305698018671,100,percent activity,1.47712125471966,33.917094056013,,1.25262406676627,1.25262406676627,1.17078671077146,100,neurodevelopment
CCTE_Shafer_MEA_dev_inter_network_spike_interval_mean_dn,"Data from the assay component CCTE_Shafer_MEA_dev_inter_network_spike_interval_mean was analyzed into 2 assay endpoints. This assay endpoint, CCTE_Shafer_MEA_dev_inter_network_spike_interval_mean_dn, was analyzed in the negative analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of functional reporter, loss-of-signal activity can be used to understand electrical activity.",, , , ,,,Active,100.173227925289,1.175898921520366,12.879470606418376,1.10989801229116,28.3962127730534,100,percent_activity,1.47712125471966,85.1886383191602,"[""Borderline active""]",1.2226703222391,1.2226703222391,0.967315685952095,100,neurodevelopment
CCTE_Shafer_MEA_dev_per_network_spike_spike_number_mean_dn,"Data from the CCTE_Shafer_MEA_dev_per_network_spike_spike_number_mean was analyzed at the assay endpoint CCTE_Shafer_MEA_dev_per_network_spike_spike_number_mean_dn in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of functional reporter, loss-of-signal activity can be used to understand electrical activity.",, , , ,,,Active,100.623072746304,1.8450008285718256,17.381498012181947,1.24008720309014,18.1794087728033,100,percent activity,1.47712125471966,54.5382263184099,,1.24923006126475,1.24923006126475,1.12080688908815,100,neurodevelopment
CCTE_Shafer_MEA_dev_per_network_spike_spike_number_mean_dn,"Data from the CCTE_Shafer_MEA_dev_per_network_spike_spike_number_mean was analyzed at the assay endpoint CCTE_Shafer_MEA_dev_per_network_spike_spike_number_mean_dn in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of functional reporter, loss-of-signal activity can be used to understand electrical activity.",, , , ,,,Active,100.623072746304,1.8450008285718256,17.381498012181947,1.24008720309014,18.1794087728033,100,percent activity,1.47712125471966,54.5382263184099,,1.24923006126475,1.24923006126475,1.12080688908815,100,neurodevelopment
CCTE_Shafer_MEA_dev_per_network_spike_spike_percent_dn,"Data from the CCTE_Shafer_MEA_dev_per_network_spike_spike_percent was analyzed at the assay endpoint CCTE_Shafer_MEA_dev_per_network_spike_spike_percent_dn in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of functional reporter, loss-of-signal activity can be used to understand electrical activity.",, , , ,,,Active,101.737521418972,1.8280409973395397,19.85307314064613,1.29782774257125,18.5512836905804,100,percent activity,1.47712125471966,55.6538510717412,,1.30807126259982,1.30807126259982,1.17854742888304,100,neurodevelopment
CCTE_Shafer_MEA_dev_per_network_spike_spike_percent_dn,"Data from the CCTE_Shafer_MEA_dev_per_network_spike_spike_percent was analyzed at the assay endpoint CCTE_Shafer_MEA_dev_per_network_spike_spike_percent_dn in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of functional reporter, loss-of-signal activity can be used to understand electrical activity.",, , , ,,,Active,101.737521418972,1.8280409973395397,19.85307314064613,1.29782774257125,18.5512836905804,100,percent activity,1.47712125471966,55.6538510717412,,1.30807126259982,1.30807126259982,1.17854742888304,100,neurodevelopment
CCTE_Shafer_MEA_dev_spike_duration_mean_dn,"Data from the assay component CCTE_Shafer_MEA_dev_spike_duration_mean was analyzed into 2 assay endpoints. This assay endpoint, CCTE_Shafer_MEA_dev_spike_duration_mean_dn, was analyzed in the negative analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of functional reporter, loss-of-signal activity can be used to understand electrical activity.",, , , ,,,Active,101.058497783106,2.376426864337603,18.605482524733937,1.26964093773363,14.1751326048452,100,percent_activity,1.47712125471966,42.5253978145356,,1.25229679517288,1.25229679517288,1.15036062393759,100,neurodevelopment
CCTE_Shafer_MEA_dev_spike_duration_mean_dn,"Data from the assay component CCTE_Shafer_MEA_dev_spike_duration_mean was analyzed into 2 assay endpoints. This assay endpoint, CCTE_Shafer_MEA_dev_spike_duration_mean_dn, was analyzed in the negative analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of functional reporter, loss-of-signal activity can be used to understand electrical activity.",, , , ,,,Active,101.058497783106,2.376426864337603,18.605482524733937,1.26964093773363,14.1751326048452,100,percent_activity,1.47712125471966,42.5253978145356,,1.25229679517288,1.25229679517288,1.15036062393759,100,neurodevelopment
CCTE_Simmons_AUR_TPO_dn,"Data from the assay component CCTE_Simmons_AUR_TPO was analyzed at the endpoint, CCTE_Simmons_AUR_TPO_dn, in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of enzyme reporter, the Amplex UltraRed assay, loss-of-signal activity can be used to understand decreased peroxidase activity in the presence of excess hydrogen peroxidase. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the oxidoreductase intended target family, where the subfamily is peroxidase.",P14650.1, , , ,,,Active,60.1344447281719,3.006722236408595,16.546500859305546,1.21870616619832,5.55295187687267,48.9309749871354,percent_activity,1.95424250943932,20,"[""Less than 50% efficacy"",""Less than 50% efficacy""]",0.650004017038399,0.435461642989171,-0.575352070762372,20,oxidoreductase
CCTE_Simmons_CellTiterGLO_HEK293T,"Data from the assay component CCTE_Simmons_CellTiterGLO_HEK293T was analyzed at the endpoint, CCTE_Simmons_CellTiterGLO_HEK293T_dn, in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of viability reporter, measures of ATP content for loss-of-signal activity can be used to understand the viability. This assay was run in parallel with aeid 1508 as a means of indicating the range of chemical cytotoxicity or reactivity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.",, , , ,,,Active,74.9168738297113,3.7458436914855655,23.096771441290542,1.36355127672218,5.60777764752233,56.8950752697913,percent_activity,1.95424250943932,20,,0.847027177103099,0.729822612699162,0.239966979503708,20,cell cycle
CCTE_Simmons_MITO_max_resp_rate_OCR_dn,"Data from the assay component CCTE_Simmons_MITO_max_resp_rate was analyzed at the endpoint, CCTE_Simmons_MITO_max_resp_rate_OCR_dn, in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of respirometric reporter, measures of maximal respiration for loss-of-signal activity can be used to understand cellular oxygen consumption as it relates to cellular respiration. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the mitochondria intended target family, where the subfamily is respiration.",, , , ,,,Active,0.247153345245926,1.23576672622963,65.700527008743,1.81756885321383,0.0389563523656356,0.204252397815114,fold change,2,0.2,"[""Only highest conc above baseline, active"",""Less than 50% efficacy"",""Borderline active"",""Only highest conc above baseline, active"",""Borderline active"",""Less than 50% efficacy""]",2.04692015640737,1.80032046958097,1.46880285439349,19.99970054626465,mitochondria
CCTE_Simmons_MITO_max_resp_rate_OCR_dn,"Data from the assay component CCTE_Simmons_MITO_max_resp_rate was analyzed at the endpoint, CCTE_Simmons_MITO_max_resp_rate_OCR_dn, in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of respirometric reporter, measures of maximal respiration for loss-of-signal activity can be used to understand cellular oxygen consumption as it relates to cellular respiration. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the mitochondria intended target family, where the subfamily is respiration.",, , , ,,,Active,0.247153345245926,1.23576672622963,65.700527008743,1.81756885321383,0.0389563523656356,0.204252397815114,fold change,2,0.2,"[""Only highest conc above baseline, active"",""Less than 50% efficacy"",""Borderline active"",""Only highest conc above baseline, active"",""Borderline active"",""Less than 50% efficacy""]",2.04692015640737,1.80032046958097,1.46880285439349,19.99970054626465,mitochondria
CCTE_Simmons_MITO_viability,"Data from the assay component CCTE_Simmons_MITO_viability was analyzed at the endpoint, CCTE_Simmons_MITO_viability, in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of viability reporter, measures of ATP content for loss-of-signal activity can be used to understand the viability. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.",, , , ,,,Active,60.320356096631,3.01601780483155,31.443153677180035,1.49752609830597,6.74146038501161,48.7633614321717,percent_activity,2,20,"[""Less than 50% efficacy"",""Less than 50% efficacy""]",1.12159920826262,1.13057325785979,0.319424096733352,19.99970054626465,cell cycle
CCTE_Simmons_MITO_viability,"Data from the assay component CCTE_Simmons_MITO_viability was analyzed at the endpoint, CCTE_Simmons_MITO_viability, in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of viability reporter, measures of ATP content for loss-of-signal activity can be used to understand the viability. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.",, , , ,,,Active,60.320356096631,3.01601780483155,31.443153677180035,1.49752609830597,6.74146038501161,48.7633614321717,percent_activity,2,20,"[""Less than 50% efficacy"",""Less than 50% efficacy""]",1.12159920826262,1.13057325785979,0.319424096733352,19.99970054626465,cell cycle
CEETOX_H295R_11DCORT_dn,"Data from the assay component CEETOX_H295R_11DCORT was analyzed into 2 assay endpoints. This assay endpoint, CEETOX_H295R_11DCORT_dn, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity using HPLC-MS-MS was used to understand synthesis of 11-Deoxycortisol in H295R cell line at 48hr of chemical exposure. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the steroid hormone intended target family, where the subfamily is glucocorticoids.","NP_000167.1|NP_000892.2", , , ,,,Active,1.5014773677384,2.5226531463732527,84.05094987500154,1.92454262584379,0.0991996177977032,1.20213221545124,log2_fold_induction,2,0.595197706786219,"[""Only highest conc above baseline, active"",""Only highest conc above baseline, active""]",1.90171750272872,1.84867369930716,1.80526231172414,100.0999984741211,steroid hormone
CEETOX_H295R_ANDR_dn,"Data from the assay component CEETOX_H295R_ANDR was analyzed into 2 assay endpoints. This assay endpoint, CEETOX_H295R_ANDR_dn, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity using HPLC-MS-MS was used to understand synthesis of Androstenedione in H295R cell line at 48hr of chemical exposure. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the steroid hormone intended target family, where the subfamily is androgens.",, , , ,,,Active,3.18617991117166,4.226850668302169,54.84821437992083,1.73916249339532,0.125632539890173,2.59671281088352,log2_fold_induction,2,0.753795239341038,,1.5282176275518,1.37746824181825,1.34352389491481,100.0999984741211,steroid hormone
CEETOX_H295R_CORTISOL_dn,"Data from the assay component CEETOX_H295R_CORTISOL was analyzed into 2 assay endpoints. This assay endpoint, CEETOX_H295R_CORTISOL_dn, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity using HPLC-MS-MS was used to understand synthesis of Cortisol in H295R cell line at 48hr of chemical exposure. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the steroid hormone intended target family, where the subfamily is glucocorticoids.","NP_000167.1|NP_000892.2", , , ,,,Active,2.01100160430096,1.9818882040476207,82.82225750454306,1.91814706398819,0.169114954802015,1.64688620245169,log2_fold_induction,2,1.01468972881209,"[""Only highest conc above baseline, active"",""Only highest conc above baseline, active""]",1.91913930865814,1.85916638436592,1.79886675023581,100.0999984741211,steroid hormone
CEETOX_H295R_MTT_cell_viability_dn,"The assay component endpoint CEETOX_H295R_MTT_cell_viability_dn was analyzed in the negative fitting direction relation to DMSO as the negative control and baseline of activity. Using a type of viability reporter in the MTT cytotoxicity assay, gain-of-signal activity can be used to monitor cellular processes to understand changes in proliferation. To generalize the intended target to other relatable targets, this assay endpoint is annotated to cell cycle, where the subfamily is proliferation.",, , , ,,,Active,59.8015731886128,2.99007865943064,82.79176437576282,1.91798713794371,5.96608141861838,48.990435706695,percent_activity,2,20,"[""Only highest conc above baseline, active"",""Only highest conc above baseline, active""]",1.88062835657572,1.87180737471472,1.79870682092625,100.0999984741211,cell cycle
CEETOX_H295R_OHPREG_dn,"Data from the assay component CEETOX_H295R_OHPREG was analyzed into 2 assay endpoints. This assay endpoint, CEETOX_H295R_OHPREG_dn, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity using HPLC-MS-MS was used to understand synthesis of 17alpha-hydroxypregnenolone in H295R cell line at 48hr of chemical exposure. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the steroid hormone intended target family, where the subfamily is progestagens.",NP_000917.3, , , ,,,Active,1.67063605190871,2.165534985189416,66.60260801827319,1.82349123556322,0.12857762349216,1.39219671046548,log2_fold_induction,2,0.77146574095296,"[""Only highest conc above baseline, active"",""Only highest conc above baseline, active""]",1.80668322999242,1.6914574255769,1.58239634332267,100.0999984741211,steroid hormone
CEETOX_H295R_PROG_up,"Data from the assay component CEETOX_H295R_PROG was analyzed into 2 assay endpoints. This assay endpoint, CEETOX_H295R_PROG_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity using HPLC-MS-MS was used to understand synthesis of  Progesterone in H295R cell line at 48hr of chemical exposure. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the steroid hormone intended target family, where the subfamily is progestagens.",NP_000917.3, , , ,,,Active,2.14865596102694,2.3489024831727794,39.826785411270386,1.60017525407473,0.152458149882028,1.76180388704067,log2_fold_induction,2,0.914748899292168,,1.50482038133066,1.18352656127323,0.900134593028895,100.0999984741211,steroid hormone
CEETOX_H295R_TESTO_dn,"Data from the assay component CEETOX_H295R_TESTO was analyzed into 2 assay endpoints. This assay endpoint, CEETOX_H295R_TESTO_dn, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity using HPLC-MS-MS was used to understand synthesis of  Testosterone in H295R cell line at 48hr of chemical exposure. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the steroid hormone intended target family, where the subfamily is androgens.",, , , ,,,Active,3.00459088556708,3.0112530729531177,55.711048029778844,1.74594132843375,0.166297928291831,2.48162867831652,log2_fold_induction,2,0.997787569750986,"[""Only highest conc above baseline, active"",""Only highest conc above baseline, active""]",1.63103244581169,1.48053499778942,1.38461360105524,100.0999984741211,steroid hormone
LTEA_HepaRG_ABCC2_up,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _up indicates curve fitting for increase in expression (induction).,NP_000383.1, , , ,,,Active,0.830958282142637,1.9362227073254052,50.68795398864893,1.70490476134822,0.143054873284778,0.63646852496288,log2_fold_induction,2,0.429164619854334,"[""Only highest conc above baseline, active"",""Only highest conc above baseline, active""]",1.72236027530903,1.72236027530903,1.12292325811344,20,transporter
LTEA_HepaRG_ACLY_dn,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,NP_001087.2, , , ,,,Active,0.558706722764111,1.5958637434084686,38.660105550099935,1.58726303540809,0.116698919330631,0.558420082730995,log2_fold_induction,2,0.350096757991893,"[""Less than 50% efficacy"",""Less than 50% efficacy""]",1.61538861981302,1.61538861981302,1.46790228173128,20,lyase
LTEA_HepaRG_BID_dn,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,NP_001187.1, , , ,,,Active,1.45185265199716,2.080184833240615,0.7200065530526223,-0.142663550872006,0.232648020630518,1.57340797491419,log2_fold_induction,-0.522878745280338,0.697944061891554,"[""Hit-call potentially confounded by overfitting"",""Borderline active"",""Noisy data"",""Hit-call potentially confounded by overfitting"",""Borderline active"",""Noisy data""]",-0.16497284290804,-0.16497284290804,-0.778176927359384,20,cell cycle
LTEA_HepaRG_CYP1A1_up,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _up indicates curve fitting for increase in expression (induction).,NP_000490.1, , , ,"[57,57]",,Active,3.63025944007244,4.031020722577395,33.38733901358182,1.52358180696184,0.300193564683644,3.62982273071584,log2_fold_induction,2,0.900580694050932,,1.46338314460069,1.46338314460069,1.40430139586578,20,cyp
LTEA_HepaRG_CYP1A2_up,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _up indicates curve fitting for increase in expression (induction).,NP_000752.2, , , ,"[131,131]",,Active,2.5077917982276,2.6411909182815623,31.78168829772522,1.50217696395099,0.316497604782422,2.50736250517402,log2_fold_induction,2,0.949492814347266,,1.47528206591626,1.47528206591626,1.38289660636698,20,cyp
LTEA_HepaRG_CYP2B6_up,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _up indicates curve fitting for increase in expression (induction).,NP_000758.1, , , ,,,Active,3.57500314730706,4.742288645675827,14.034875879963645,1.14720857622338,0.251285361310856,2.91850118318043,log2_fold_induction,2,0.753856083932568,,0.380458680310655,0.380458680310655,-0.129388441373856,20,cyp
LTEA_HepaRG_CYP2C19_up,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _up indicates curve fitting for increase in expression (induction).,NP_000760.1, , , ,,,Active,1.05496008689009,1.8811309220560055,31.46607628270906,1.49784259118115,0.186937207917646,0.83361649401033,log2_fold_induction,2,0.560811623752938,"[""Only highest conc above baseline, active"",""Only highest conc above baseline, active""]",1.56027195334967,1.56027195334967,0.413904621297516,20,cyp
LTEA_HepaRG_CYP2E1_dn,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,NP_000764.1, , , ,,,Active,1.98826196114236,4.151488563302966,63.78493505228663,1.80471811765171,0.159642493756543,1.49958421598505,log2_fold_induction,2,0.478927481269629,,1.60284438308391,1.60284438308391,1.41829802019466,20,cyp
LTEA_HepaRG_CYP3A4_up,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _up indicates curve fitting for increase in expression (induction).,NP_059488.2, , , ,,,Active,2.05913585119752,1.7353522145828895,30.255663141711064,1.48080667621175,0.395526977922934,1.79490525257316,log2_fold_induction,2,1.1865809337688,"[""Only highest conc above baseline, active"",""Only highest conc above baseline, active""]",1.56672302384494,1.56672302384494,0.866707731009778,20,cyp
LTEA_HepaRG_CYP3A7_up,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _up indicates curve fitting for increase in expression (induction).,NP_000756.3, , , ,,,Active,1.76435042453651,2.27339129700695,50.374917060924794,1.7022143441117,0.258695812266514,1.10166441567254,log2_fold_induction,2,0.776087436799542,"[""Only highest conc above baseline, active"",""Only highest conc above baseline, active""]",1.56109265424119,1.56109265424119,0.419231237526974,20,cyp
LTEA_HepaRG_CYP7A1_dn,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,NP_000771.2, , , ,,,Active,1.03279506553453,1.9228330250033,54.7361598684815,1.73827432529133,0.179040518530855,0.822483606552305,log2_fold_induction,2,0.537121555592565,,1.7539864945745,1.7539864945745,1.30838428652008,20,cyp
LTEA_HepaRG_DDIT3_dn,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,NP_001181982.1, , , ,,,Active,1.5004998901075,2.610410057224529,82.88786244624903,1.91849093997676,0.191604621140491,0.894159878810983,log2_fold_induction,2,0.574813863421473,"[""Hit-call potentially confounded by overfitting"",""Borderline active"",""Only highest conc above baseline, active"",""Hit-call potentially confounded by overfitting"",""Borderline active"",""Only highest conc above baseline, active""]",1.81251325858017,1.81251325858017,1.42979792888446,20,dna binding
LTEA_HepaRG_FABP1_dn,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,NP_001434.1, , , ,,,Active,0.897415019682991,1.85956493907997,34.473817740092024,1.53748938122183,0.160864691309103,0.897235169840554,log2_fold_induction,2,0.482594073927309,"[""Only highest conc above baseline, active"",""Only highest conc above baseline, active""]",1.54570454489883,1.54570454489883,1.41820906373871,20,transporter
LTEA_HepaRG_FASN_dn,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,NP_004095.4, , , ,"[58,34,34,58]",,Active,0.449974735491668,1.2243021579863906,36.033044871460575,1.55670096251114,0.122511895873739,0.449839291893456,log2_fold_induction,2,0.367535687621217,"[""Borderline active"",""Less than 50% efficacy"",""Only highest conc above baseline, active"",""Borderline active"",""Less than 50% efficacy"",""Only highest conc above baseline, active""]",1.63784679722798,1.63784679722798,1.43742062501118,20,lyase
LTEA_HepaRG_GADD45A_dn,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,NP_001915.1, , , ,,,Active,2.31406073734596,3.8211915735249598,5.2267167205684055,0.718228962690473,0.201862053831487,1.19605548139417,log2_fold_induction,-0.522878745280338,0.605586161494461,"[""Hit-call potentially confounded by overfitting"",""Borderline active"",""Borderline active"",""Hit-call potentially confounded by overfitting""]",-0.148430326769516,-0.148430326769516,-1.11779084491588,20,cell cycle
LTEA_HepaRG_GSTA2_up,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _up indicates curve fitting for increase in expression (induction).,NP_000837.3, , , ,,,Active,0.856053668869778,1.3012972663770392,0.3114465835374625,-0.506616428825691,0.219282119719688,0.695065334825058,log2_fold_induction,0,0.657846359159064,"[""Hit-call potentially confounded by overfitting"",""Borderline active"",""Only one conc above baseline, active"",""Hit-call potentially confounded by overfitting"",""Borderline active"",""Only one conc above baseline, active""]",-0.44149081138021,-0.44149081138021,-0.625896772490063,20,transferase
LTEA_HepaRG_HIF1A_dn,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,NP_001521.1, , , ,"[122,123,220,150,122,123,220,150]",[801],Active,0.864170945204825,2.1868931491502335,90.72012717990036,1.9577036503836,0.131719733013418,0.549011497652448,log2_fold_induction,-1,0.395159199040254,"[""Less than 50% efficacy"",""Less than 50% efficacy""]",1.93353573866725,1.93353573866725,1.64777829497838,20,dna binding
LTEA_HepaRG_HMGCS2_dn,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,NP_005509.1, , , ,"[60,60]",,Active,0.693275320260782,1.3242775915816198,31.630546844586213,1.50010670027909,0.174504027621778,0.693200489824301,log2_fold_induction,2,0.523512082865334,"[""Borderline active"",""Only highest conc above baseline, active"",""Borderline active"",""Only highest conc above baseline, active""]",1.5612421363403,1.5612421363403,1.3808262823795,20,lyase
LTEA_HepaRG_IL6R_up,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _up indicates curve fitting for increase in expression (induction).,NP_000556.1, , , ,,,Active,0.69935879965332,1.7860681003094947,0.2798711962610512,-0.55304179588388,0.130521114981027,0.4853819147111,log2_fold_induction,0,0.391563344943081,"[""Less than 50% efficacy"",""Only one conc above baseline, active"",""Hit-call potentially confounded by overfitting"",""Less than 50% efficacy"",""Only one conc above baseline, active"",""Hit-call potentially confounded by overfitting""]",-0.53997430939594,-0.53997430939594,-0.67232218291698,20,cytokine receptor
LTEA_HepaRG_KCNK1_up,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _up indicates curve fitting for increase in expression (induction).,NP_002236.1, , , ,,,Active,0.729220410771181,1.027068936733949,41.88459622540167,1.62205433312627,0.236667142353684,0.728531306728172,log2_fold_induction,2,0.710001427061052,"[""Only highest conc above baseline, active"",""Hit-call potentially confounded by overfitting"",""Borderline active"",""Only highest conc above baseline, active"",""Hit-call potentially confounded by overfitting"",""Borderline active""]",1.81832870455268,1.81832870455268,1.5025711387022,20,ion channel
LTEA_HepaRG_NFE2L2_dn,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,NP_006155.2, , , ,"[61,61]",[478],Active,0.681923885120245,2.2189945577108263,0.09239869041501166,-1.03433418407821,0.102437367823581,0.442693890703895,log2_fold_induction,-1,0.307312103470743,"[""Hit-call potentially confounded by overfitting"",""Only one conc above baseline, active"",""Less than 50% efficacy"",""Borderline active"",""Hit-call potentially confounded by overfitting"",""Only one conc above baseline, active"",""Less than 50% efficacy"",""Borderline active""]",-1.04540746226383,-1.04540746226383,-1.15719901780235,20,dna binding
LTEA_HepaRG_SLCO1B1_dn,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,NP_006437.3, , , ,,,Active,0.60513105421868,1.1151280466920512,34.80135401885021,1.54159614140277,0.180885371867909,0.604999820318795,log2_fold_induction,2,0.542656115603727,"[""Borderline active"",""Only highest conc above baseline, active"",""Hit-call potentially confounded by overfitting"",""Borderline active"",""Only highest conc above baseline, active"",""Hit-call potentially confounded by overfitting""]",1.65899433721519,1.65899433721519,1.4222692368115,20,transporter
LTEA_HepaRG_UGT1A1_up,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _up indicates curve fitting for increase in expression (induction).,NP_000454.1, , , ,,,Active,1.91929207458575,2.8977601809964826,37.525819027821015,1.57433017980622,0.220778803248623,1.7618834994082,log2_fold_induction,2,0.662336409745869,,1.46125690602015,1.46125690602015,1.18653975149378,20,transferase
NVS_ENZ_hDUSP3,"Data from the assay component NVS_ENZ_hDUSP3 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hDUSP3, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene DUSP3. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""phosphatase"" intended target family, where the subfamily is ""dual-specific phosphatase"".",NP_004081.1, , , ,,,Active,28.569817629604,1.4284908814802,9.139184937677275,0.960907465662375,1.28111925368239,23.8081813586344,percent_activity,1.30102999566398,20,"[""Hit-call potentially confounded by overfitting"",""Less than 50% efficacy"",""Borderline active"",""Hit-call potentially confounded by overfitting"",""Less than 50% efficacy"",""Borderline active""]",1.14497617921701,0.55659512557809,0.483683786878135,20,phosphatase
NVS_ENZ_hES,"Data from the assay component NVS_ENZ_hES was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hES, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene BCHE. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""esterase"" intended target family, where the subfamily is ""pseudocholinesterase"".",NP_000046.1, , , ,,,Active,41.7139614020929,2.085698070104645,28.564007794811136,1.45581914291705,0.617281041838184,34.7616345062429,percent_activity,1.69897000433602,20,"[""Less than 50% efficacy"",""Less than 50% efficacy""]",1.44306647623762,0.97978468339961,1.11503350860146,20,esterase
NVS_LGIC_rGABAR_NonSelective,"Data from the assay component NVS_LGIC_rGABAR_NonSelective was analyzed into 1 assay endpoint. This assay endpoint, NVS_LGIC_rGABAR_NonSelective, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene Gabra1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""ion channel"" intended target family, where the subfamily is ""ligand-gated ion channel"".",NP_034380.1, , , ,"[10,10]",,Active,83.8390911886113,2.6545087665199825,12.34889939549861,1.09162825251378,5.26394263262771,69.8659093301946,percent_activity,1.69897000433602,31.5836557957663,,0.804880648743522,0.259748169573933,-0.15969983744102,20,ion channel
OT_AR_ARSRC1_0480,"Data from the assay component OT_AR_ARSRC1_0480 was analyzed into 1 assay endpoint. 
This assay endpoint, OT_AR_ARSRC1_0480, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, measures of receptor for gain-of-signal activity can be used to understand the binding at the pathway-level as they relate to the gene AR. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""nuclear receptor"" intended target family, where the subfamily is ""steroidal"".",NP_005408.1, , , ,,,Active,48.5845054327814,2.42922527163907,97.90741569329474,1.99081558733641,2.45637869822485,28.1818181818182,percent_activity,2,20,"[""Only highest conc above baseline, active"",""Less than 50% efficacy"",""Less than 50% efficacy"",""Only highest conc above baseline, active""]",1.97094214309714,1.89501824304615,1.86854607524548,20,nuclear receptor
OT_AR_ARSRC1_0960,"Data from the assay component OT_AR_ARSRC1_0960 was analyzed into 1 assay endpoint. 
This assay endpoint, OT_AR_ARSRC1_0960, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, measures of receptor for gain-of-signal activity can be used to understand the binding at the pathway-level as they relate to the gene AR. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""nuclear receptor"" intended target family, where the subfamily is ""steroidal"".",NP_005408.1, , , ,,,Active,53.5442306120069,2.677211530600345,85.06978424483718,1.92977533134263,1.6382320441989,41.6666666666667,percent_activity,2,20,"[""Only highest conc above baseline, active"",""Less than 50% efficacy"",""Only highest conc above baseline, active"",""Less than 50% efficacy""]",1.90170185077328,1.80534989840897,1.81049501495529,20,nuclear receptor
OT_ER_ERaERa_0480,"Data from the assay component OT_ER_ERaERa_0480 was analyzed into 1 assay endpoint. 
This assay endpoint, OT_ER_ERaERa_0480, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, measures of receptor for gain-of-signal activity can be used to understand the binding at the pathway-level as they relate to the gene ESR1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""nuclear receptor"" intended target family, where the subfamily is ""steroidal"".",NP_000116.2, , , ,"[30,200,29,165,53,52,167,112,30,67,200,29,165,53,52,67,112,167]",[1181],Active,61.6376717715371,3.081883588576855,67.01284250326565,1.8261580399222,1.66499024557606,47.8099232639054,percent_activity,2,20,"[""Only highest conc above baseline, active"",""Less than 50% efficacy"",""Only highest conc above baseline, active"",""Less than 50% efficacy""]",1.72910859989787,1.50476586746222,1.53535311632806,20,nuclear receptor
OT_ER_ERaERa_1440,"Data from the assay component OT_ER_ERaERa_1440 was analyzed into 1 assay endpoint. 
This assay endpoint, OT_ER_ERaERa_1440, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, measures of receptor for gain-of-signal activity can be used to understand the binding at the pathway-level as they relate to the gene ESR1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""nuclear receptor"" intended target family, where the subfamily is ""steroidal"".",NP_000116.2, , , ,"[200,29,165,53,52,30,67,112,167,200,29,165,53,52,167,112,30,67]",[1181],Active,43.5265619623041,2.176328098115205,94.32612383460807,1.97463198824103,0.639607305334083,23.2822302796877,percent_activity,2,20,"[""Hit-call potentially confounded by overfitting"",""Less than 50% efficacy"",""Borderline active"",""Hit-call potentially confounded by overfitting"",""Less than 50% efficacy"",""Borderline active""]",1.94742416985627,1.45918851891363,1.60651317626351,20,nuclear receptor
OT_ER_ERaERb_0480,"Data from the assay component OT_ER_ERaERb_0480 was analyzed into 1 assay endpoint. 
This assay endpoint, OT_ER_ERaERb_0480, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, measures of receptor for gain-of-signal activity can be used to understand the binding at the pathway-level as they relate to the gene ESR1 and ESR2. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""nuclear receptor"" intended target family, where the subfamily is ""steroidal"".","NP_000116.2|NP_001428.1", , , ,,,Active,150.426151731903,6.45612677032068,64.03979986195658,1.80644996598643,4.65995037220843,101.340123291343,percent_activity,2,23.2997518610421,,1.35369659357587,1.1985106928944,1.22014839203822,20,nuclear receptor
OT_ER_ERaERb_1440,"Data from the assay component OT_ER_ERaERb_1440 was analyzed into 1 assay endpoint. 
This assay endpoint, OT_ER_ERaERb_1440, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, measures of receptor for gain-of-signal activity can be used to understand the binding at the pathway-level as they relate to the gene ESR1 and ESR2. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""nuclear receptor"" intended target family, where the subfamily is ""steroidal"".","NP_000116.2|NP_001428.1", , , ,,,Active,57.0954766168466,2.85477383084233,56.54634169549796,1.75240451318984,1.91268599454975,46.530977102386,percent_activity,2,20,"[""Less than 50% efficacy"",""Less than 50% efficacy""]",1.64984373555564,1.38854107321285,1.38762198789137,20,nuclear receptor
OT_ER_ERbERb_0480,"Data from the assay component OT_ER_ERbERb_0480 was analyzed into 1 assay endpoint. 
This assay endpoint, OT_ER_ERbERb_0480, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, measures of receptor for gain-of-signal activity can be used to understand the binding at the pathway-level as they relate to the gene ESR2. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""nuclear receptor"" intended target family, where the subfamily is ""steroidal"".",NP_001428.1, , , ,,,Active,35.435925585516,1.7717962792758002,56.571494664314145,1.75259765330093,3.03794948946985,29.0277014831672,percent_activity,2,20,"[""Only highest conc above baseline, active"",""Less than 50% efficacy"",""Only highest conc above baseline, active"",""Less than 50% efficacy""]",1.79941791009826,1.56089291124421,1.35545148516348,20,nuclear receptor
OT_FXR_FXRSRC1_0480,"Data from the assay component OT_FXR_FXRSRC1_0480 was analyzed into 1 assay endpoint. 
This assay endpoint, OT_FXR_FXRSRC1_0480, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, measures of receptor for gain-of-signal activity can be used to understand the binding at the pathway-level as they relate to the gene NR1H4. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""nuclear receptor"" intended target family, where the subfamily is ""non-steroidal"".","NP_005408.1|NP_001193922.1", , , ,,,Active,88.412753269886,3.527529294737841,36.331164710929954,1.56027932077551,5.01272964064537,89.7164688372219,percent_activity,2,25.0636482032268,,1.50994204427904,1.47423514052496,1.44099841051339,20,nuclear receptor
OT_FXR_FXRSRC1_1440,"Data from the assay component OT_FXR_FXRSRC1_1440 was analyzed into 1 assay endpoint. 
This assay endpoint, OT_FXR_FXRSRC1_1440, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, measures of receptor for gain-of-signal activity can be used to understand the binding at the pathway-level as they relate to the gene NR1H4. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""nuclear receptor"" intended target family, where the subfamily is ""non-steroidal"".","NP_005408.1|NP_001193922.1", , , ,,,Active,82.4708174148405,1.9814180418684866,44.37899995848343,1.64717751156418,8.32442378863878,82.1515509341527,percent_activity,2,41.6221189431939,"[""Only highest conc above baseline, active"",""Only highest conc above baseline, active""]",1.64819577306574,1.60190505729698,1.52789530060568,20,nuclear receptor
OT_NURR1_NURR1RXRa_0480,"Data from the assay component OT_NURR1_NURR1RXRa_0480 was analyzed into 1 assay endpoint. 
This assay endpoint, OT_NURR1_NURR1RXRa_0480, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, measures of receptor for gain-of-signal activity can be used to understand the binding at the pathway-level as they relate to the gene RXRA. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""nuclear receptor"" intended target family, where the subfamily is ""non-steroidal"".","NP_006177.1|NP_002948.1", , , ,,,Active,39.9357329822582,1.9772853219035356,39.41125113227131,1.59562022200635,4.03945070950227,40.5246014298387,percent_activity,2,20.1972535475113,"[""Less than 50% efficacy"",""Only highest conc above baseline, active"",""Only highest conc above baseline, active"",""Less than 50% efficacy""]",1.59686757388407,1.55051027470558,1.47633762445225,20,nuclear receptor
OT_NURR1_NURR1RXRa_1440,"Data from the assay component OT_NURR1_NURR1RXRa_1440 was analyzed into 1 assay endpoint. 
This assay endpoint, OT_NURR1_NURR1RXRa_1440, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, measures of receptor for gain-of-signal activity can be used to understand the binding at the pathway-level as they relate to the gene RXRA. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""nuclear receptor"" intended target family, where the subfamily is ""non-steroidal"".","NP_006177.1|NP_002948.1", , , ,,,Active,188.061961718123,7.2941275925643545,103.93139470521314,2.01674675533123,5.15653062910042,83.8474059852248,percent_activity,2,25.7826531455021,"[""Noisy data"",""Only highest conc above baseline, active"",""Noisy data"",""Only highest conc above baseline, active""]",1.91687978534792,1.88580387777183,1.8974664092057,20,nuclear receptor
TAMU_PeakParms_SingleDonor1434_Asystole,"Data from the assay component TAMU_PeakParms_SingleDonor1434_Asystole was analyzed into 1 assay endpoint. This assay endpoint, TAMU_PeakParms_SingleDonor1434_Asystole, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of functional reporter, loss-of-signal activity can be used to understand changes in the cardiac function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cardiomyocyte function intended target family, where the subfamily is cessation of beating.",, , , ,,,Active,103.46660569087169,1.0891221651670704,68.38108440097326,1.834935983644323,9.724331715171544,100,percent_activity,2,95,"[""Borderline active"",""Only highest conc above baseline, active""]",1.9725392906564685,1.781733967889218,1.7098834690255718,20,cardiomyocyte function
TOX21_AhR_LUC_Agonist,"Data from the assay component TOX21_AhR_LUC_Agonist was analyzed into 1 assay endpoint. This assay endpoint, TOX21_AhR_LUC_Agonist, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene AHR. Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the DNA binding intended target family, where the subfamily is basic helix-loop-helix protein.",NP_001612.1, , , ,"[57,131,21,41,150,310,131,21,57,310,41,150]",[165],Active,89.4856161844207,4.474280809221035,39.377219521219686,1.59524504676341,1.20983399992497,61.7442599469,percent_activity,1.95424250943932,20,,0.374828170086166,-1.50490105797128,-0.557924118790047,20,dna binding
TOX21_AP1_BLA_Agonist_ch1,"Data from the assay component TOX21_AP1_BLA_Agonist_ch1 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_AP1_BLA_Agonist_ch1, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene JUN|FOS|JUN. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves as artifact detection function.",, , , ,,,Active,66.6880485707916,3.3344024285395797,209.47569546772164,2.32113364097022,2.57591984669775,21.1875662822,percent_activity,1.90308998699194,20,"[""Less than 50% efficacy"",""Borderline active"",""Less than 50% efficacy"",""Borderline active""]",1.93318786264471,1.39123942459139,1.31565086051036,20,channel 1
TOX21_AP1_BLA_Agonist_ch2,"Data from the assay component TOX21_AP1_BLA_Agonist_ch2 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_AP1_BLA_Agonist_ch2, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, increased activity can be used to understand changes in the reporter gene as they relate to the gene JUN|FOS|JUN. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves as artifact detection function.",, , , ,,,Active,39.1992866751476,1.8396476031192512,23.810479182353664,1.37676813560471,3.55134017774949,38.1239708223,percent_activity,1.90308998699194,21.3080410664969,"[""Less than 50% efficacy"",""Less than 50% efficacy""]",1.38906786720673,1.30740932579274,1.2221374243226,20,channel 2
TOX21_AP1_BLA_Agonist_ratio,"Data from the assay component TOX21_AP1_BLA_Agonist_ratio was analyzed into 1 assay endpoint. This assay endpoint, TOX21_AP1_BLA_Agonist_ratio, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene JUN|FOS|JUN. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints and this ratio serves a reporter gene function to understand target activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the dna binding intended target family, where the subfamily is basic leucine zipper.",NP_002219.1, , , ,,,Active,33.7405974658932,1.68702987329466,21.921006159404172,1.34086048409375,2.7369041511147,34.2303189501,percent_activity,1.90308998699194,20,"[""Less than 50% efficacy"",""Less than 50% efficacy""]",1.36433041589048,1.26993314902239,1.20348221709449,20,dna binding
TOX21_ARE_BLA_agonist_ratio,"Data from the assay component TOX21_ARE_BLA_Agonist_ratio was analyzed into 1 assay endpoint.  This assay endpoint, TOX21_ARE_BLA_Agonist_ratio, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity.  Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene NFE2L2. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints and this ratio serves a reporter gene function to understand target activity.  To generalize the intended target to other relatable targets, this assay endpoint is annotated to the DNA binding intended target family, where the subfamily is basic leucine zipper.  ",NP_006155.2, , , ,"[61,61]",[478],Active,25.8411648881859,1.292058244409295,37.06585517357451,1.56897402450039,2.50978290890691,20.6585138979,percent_activity,1.95424250943932,20,"[""Less than 50% efficacy"",""Borderline active"",""Less than 50% efficacy"",""Borderline active""]",2.00113103548571,1.25692192626749,0.797488454047043,20,dna binding
TOX21_CAR_Agonist,"Data from the assay component TOX21_CAR_Agonist was analyzed into 1 assay endpoint. This assay endpoint, TOX21_CAR_Agonist, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene NR1I3. Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family.",NP_001070948.1, , , ,,,Active,50.3309309212836,2.51654654606418,39.70136247671419,1.59880541119549,0.83822208889671,38.2316693376,percent_activity,1.95424250943932,20,"[""Less than 50% efficacy"",""Less than 50% efficacy""]",1.38287184329281,0.0716235630538475,0.459483071569543,20,nuclear receptor
TOX21_DT40,"Data from the assay component TOX21_DT40 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_DT40, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of viability reporter, loss-of-signal activity can be used to understand changes in the viability. Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint.",, , , ,,,Active,57.1096998668228,2.379509543026002,58.98058067297546,1.77070904393344,4.0001030208237,41.4289537606,percent_activity,1.95424250943932,24.0006181249422,"[""Less than 50% efficacy"",""Less than 50% efficacy""]",1.72837048192968,1.59645333190636,1.48156007450255,20,cell cycle
TOX21_DT40_100,"Data from the assay component TOX21_DT40_100 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_DT40_100, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of viability reporter, loss-of-signal activity can be used to understand changes in the viability as they relate to the gene Ku70 - Rad54 (-/-). Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the DNA repair family.",, , , ,,,Active,43.3314056795821,2.0089301602604976,35.568684643506515,1.5510678049488,3.59489896137582,40.7769389164,percent_activity,1.95424250943932,21.5693937682549,"[""Less than 50% efficacy"",""Less than 50% efficacy""]",1.55018118582832,1.4409152825176,1.33194666884772,20,cell cycle
TOX21_DT40_657,"Data from the assay component TOX21_DT40_657 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_DT40_657, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of viability reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene Rev3. Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the DNA repair family.",, , , ,,,Active,114.508532118209,4.3702185094835695,102.19403088313506,2.00942552955384,4.36700254498032,38.09205585555,percent_activity,1.95424250943932,26.2020152698819,"[""Only highest conc above baseline, active"",""Less than 50% efficacy"",""Only highest conc above baseline, active"",""Less than 50% efficacy""]",1.90894477367133,1.84017988691651,1.82771124143153,20,cell cycle
TOX21_H2AX_HTRF_CHO_Agonist_ratio,"Data from the assay component TOX21_H2AX_HTRF_CHO_Agonist_ratio was analyzed into 1 assay endpoint. This assay endpoint, TOX21_H2AX_HTRF_CHO_Agonist_ratio, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene H2AFX. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this ratio serves a reporter gene function to understand target activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the dna binding intended target family, where the subfamily is histone.",NP_002096.1, , , ,,,Active,48.3491477967338,2.4174573898366902,101.14544034400282,2.00494630946893,1.1538473582706,48.2833621778,percent_activity,2.30102999566398,20,"[""Only highest conc above baseline, active"",""Less than 50% efficacy"",""Only highest conc above baseline, active"",""Less than 50% efficacy""]",1.98600755691692,1.86583919887111,1.88566598951112,20,dna binding
TOX21_H2AX_HTRF_CHO_viability,"TOX21_H2AX_HTRF_CHO_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.",, , , ,,,Active,31.4623647984879,1.573118239924395,139.69417971022088,2.14517831182362,2.15763115046871,22.3326639467,percent_activity,2.30102999566398,20,"[""Less than 50% efficacy"",""Only highest conc above baseline, active"",""Borderline active"",""Less than 50% efficacy"",""Borderline active"",""Only highest conc above baseline, active""]",2.2453371138301,1.90212713785032,1.74983806104406,20,cell cycle
TOX21_MMP_ratio_down,"Data from the assay component TOX21_MMP_ratio was analyzed into 2 assay endpoints. This assay endpoint, TOX21_MMP_ratio_down, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of 6 membrane potential reporter, loss-of-signal activity can be used to understand changes in the signaling. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell morphology intended target family, where the subfamily is organelle conformation.",, , , ,,,Active,42.0204467081012,1.086824265504831,30.260649429627357,1.48087824426473,6.44391923052108,41.0772257087,percent_activity,1.95424250943932,38.6635153831265,"[""Borderline active"",""Less than 50% efficacy"",""Borderline active"",""Less than 50% efficacy""]",1.78451592285455,1.46098452563109,1.20788483429991,20,cell morphology
TOX21_MMP_viability,"TOX21_MMP_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.",, , , ,,,Active,24.9353153534219,1.246765767671095,38.14333115198495,1.5814186183836,3.32276785161468,23.9105762351,percent_activity,1.95424250943932,20,"[""Borderline active"",""Less than 50% efficacy"",""Less than 50% efficacy"",""Borderline active""]",1.72627578153262,1.53934414044893,1.35396192739041,20,cell cycle
TOX21_PR_BLA_Agonist_ch2,"Data from the assay component TOX21_PR_BLA_Agonist_ch2 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_PR_BLA_Agonist_ch2, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene NR3C3. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves as artifact detection function.",, , , ,,,Active,33.673245597012,1.6836622798506,68.7393072074723,1.83720515076472,2.83449299466102,21.5090624867,percent_activity,1.95424250943932,20,"[""Less than 50% efficacy"",""Borderline active"",""Less than 50% efficacy"",""Borderline active""]",1.92157857459511,1.59644399936678,1.34971727899083,20,channel 2
TOX21_PR_BLA_Antagonist_ch1,"Data from the assay component TOX21_PR_BLA_Antagonist_ch1 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_PR_BLA_Antagonist_ch1, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, increased activity can be used to understand changes in the reporter gene as they relate to the gene NR3C3. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves as artifact detection function.",, , , ,,,Active,54.1624959560447,1.9012766869447417,32.14435845155294,1.50710476238151,4.74790582629342,48.3552821676,percent_activity,1.95424250943932,28.4874349577605,"[""Less than 50% efficacy"",""Less than 50% efficacy""]",1.53009231321274,1.27919728873132,1.02117669140779,20,channel 1
TOX21_PR_BLA_Antagonist_ch2,"Data from the assay component TOX21_PR_BLA_Antagonist_ch2 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_PR_BLA_Antagonist_ch2, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene NR3C3. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves as artifact detection function.",, , , ,,,Active,59.6332406313995,1.4353892797815293,13.102158960110048,1.11734286414491,6.92416585421295,59.14627082415,percent_activity,1.95424250943932,41.5449951252777,,1.29426425967035,0.984073376246675,0.64983938623479,20,channel 2
TOX21_PR_BLA_Antagonist_ratio,"Data from the assay component TOX21_PR_BLA_Antagonist_ratio was analyzed into 1 assay endpoint. This assay endpoint, TOX21_PR_BLA_Antagonist_ratio, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity an be used to understand changes in the reporter gene as they relate to the gene NR3C3. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints and this ratio serves a reporter gene function to understand target activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.",NP_000917.3, , , ,,,Active,80.4694121274224,4.02347060637112,15.88044059353829,1.20086254750468,2.51198214229767,68.8356190579,percent_activity,1.95424250943932,20,,0.800515916299761,0.379525187724333,0.405809057830571,20,nuclear receptor
TOX21_PXR_Agonist,"Data from the assay component TOX21_PXR_Agonist was analyzed into 1 assay endpoint. This assay endpoint, TOX21_PXR_Agonist, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to gene NR1I2. Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor target family, where the subfamily is non-steroidal.",NP_071285.1, , , ,,,Active,27.3837802380933,1.369189011904665,36.56768225452777,1.56309743460744,1.80636679455099,27.4727852007,percent_activity,1.95424250943932,20,"[""Less than 50% efficacy"",""Less than 50% efficacy""]",1.71570167361726,1.34876528360384,1.22659590488658,20,nuclear receptor
TOX21_RAR_LUC_Agonist_viability,"TOX21_RAR_LUC_Agonist_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.",, , , ,,,Active,113.480674926266,5.674033746313301,111.08696884631034,2.04566311663605,1.53553439731881,51.6024539067,percent_activity,1.95424250943932,20,,1.8102063341178,1.56273925525263,1.7101612389534,20,cell cycle
TOX21_RT_HEK293_FLO_08hr_viability,"TOX21_RT_HEK293_FLO_08hr_viability used a dead cell DNA stain where an increase in measured fluorescence indicated a loss of cell viability.  The assay component endpoint is part of a kinetic analysis of cell death with additional exposure times measured in other assay components as well as live cells measured with a vital dye, e.g. TOX21_RT_HEK293_GLO_08hr_viability",, , , ,,,Active,51.4145681094107,2.1831488483121224,42.658425958286436,1.63000482649451,3.92510785122456,42.8454734518,percent_activity,1.90308998699194,23.5506471073474,"[""Less than 50% efficacy"",""Less than 50% efficacy""]",1.59769871221908,1.39683953525418,1.20793298918367,20,cell cycle
TOX21_RT_HEK293_GLO_08hr_viability,"TOX21_RT_HEK293_GLO_08hr_viability used a dead cell DNA stain where an increase in measured fluorescence indicated a loss of cell viability.  The assay component endpoint is part of a kinetic analysis of cell death with additional exposure times measured in other assay components as well as live cells measured with a vital dye, e.g. TOX21_RT_HEK293_FLO_08hr_viability",, , , ,,,Active,74.6301516035775,3.073881831878226,172.17088233044976,2.23595970511722,4.04646609105207,43.19074293775,percent_activity,1.90308998699194,24.2787965463124,"[""Less than 50% efficacy"",""Less than 50% efficacy""]",1.83440684109137,1.33391768085428,1.02636956115518,20,cell cycle
TOX21_RT_HEK293_GLO_16hr_viability,"TOX21_RT_HEK293_GLO_16hr_viability used a dead cell DNA stain where an increase in measured fluorescence indicated a loss of cell viability.  The assay component endpoint is part of a kinetic analysis of cell death with additional exposure times measured in other assay components as well as live cells measured with a vital dye, e.g. TOX21_RT_HEK293_FLO_08hr_viability",, , , ,,,Active,82.2051397809363,3.4101170036576316,238.2984898977922,2.37712129022252,4.0177086637968,44.1358949479,percent_activity,1.90308998699194,24.1062519827808,"[""Less than 50% efficacy"",""Less than 50% efficacy""]",1.8202178373711,1.26205463615402,0.986105809868376,20,cell cycle
TOX21_RT_HEK293_GLO_24hr_viability,"TOX21_RT_HEK293_GLO_24hr_viability used a dead cell DNA stain where an increase in measured fluorescence indicated a loss of cell viability.  The assay component endpoint is part of a kinetic analysis of cell death with additional exposure times measured in other assay components as well as live cells measured with a vital dye, e.g. TOX21_RT_HEK293_FLO_08hr_viability",, , , ,,,Active,77.5400514236779,3.1603640363873717,252.9539858826621,2.40304152712552,4.08919407864135,42.09872211325,percent_activity,1.90308998699194,24.5351644718481,"[""Less than 50% efficacy"",""Less than 50% efficacy""]",1.98227753719506,1.48992379022527,1.20280669139564,20,cell cycle
TOX21_RT_HEK293_GLO_32hr_viability,"TOX21_RT_HEK293_GLO_32hr_viability used a dead cell DNA stain where an increase in measured fluorescence indicated a loss of cell viability.  The assay component endpoint is part of a kinetic analysis of cell death with additional exposure times measured in other assay components as well as live cells measured with a vital dye, e.g. TOX21_RT_HEK293_FLO_08hr_viability",, , , ,,,Active,48.5259323122207,1.9315803624448535,112.68384099583139,2.05186164213752,4.18706647811088,39.33766869825,percent_activity,1.90308998699194,25.1223988686653,"[""Less than 50% efficacy"",""Borderline active"",""Hit-call potentially confounded by overfitting"",""Less than 50% efficacy"",""Borderline active"",""Hit-call potentially confounded by overfitting""]",2.08782159008811,1.51812797997735,0.937018451320072,20,cell cycle
TOX21_RXR_BLA_Agonist_viability,"TOX21_RXR_BLA_Agonist_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.",, , , ,,,Active,33.3634660949519,1.25284066294636,32.18753547928814,1.50768772509441,4.43837580224682,32.7404573396,percent_activity,1.90308998699194,26.6302548134809,"[""Less than 50% efficacy"",""Less than 50% efficacy""]",1.61226275998764,1.47656263838376,1.3405782398955,20,cell cycle
TOX21_TR_LUC_GH3_Antagonist,"Data from the assay component TOX21_TR_LUC_GH3_Antagonist was analyzed into 1 assay endpoint. This assay endpoint, TOX21_TR_LUC_GH3_Antagonist, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene THRA and THRB. Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.","NP_003241.2|NP_000452.2", , , ,,,Active,53.9321500922899,2.403742418394378,51.07048118570146,1.70816994979426,3.73945711206963,75.1407161295,percent_activity,1.95424250943932,22.4367426724178,"[""Only highest conc above baseline, active"",""Only highest conc above baseline, active""]",1.68957758748978,1.63487492440756,1.58771416326654,20,nuclear receptor
TOX21_TR_LUC_GH3_Antagonist_viability,"TOX21_TR_LUC_GH3_Antagonist_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.",, , , ,,,Active,79.7834794200216,1.9908369758714843,53.722377894051554,1.73015522744064,6.67922423139783,66.5746023305,percent_activity,1.95424250943932,40.075345388387,"[""Only highest conc above baseline, active"",""Only highest conc above baseline, active""]",1.73065495207429,1.67084767579184,1.61087484791834,20,cell cycle
TOX21_TSHR_HTRF_Antagonist_ch1,"Data from the assay component TOX21_TSHR_HTRF_Antagonist_ch1 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_TSHR_HTRF_Antagonist_ch1, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, increased activity can be used to understand changes in the reporter gene as they relate to the gene TSHR. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves as artifact detection function.",, , , ,,,Active,76.8783025479355,3.8439151273967753,52.87670631252785,1.72326439513787,1.90228676304723,62.1313581116,percent_activity,1.95424250943932,20,,1.54069207509051,1.28247296264098,1.33945323510597,20,channel 1
TOX21_TSHR_HTRF_Antagonist_ratio,"Data from the assay component TOX21_TSHR_HTRF_Antagonist_ratio was analyzed into 1 assay endpoint. This assay endpoint, TOX21_TSHR_HTRF_Antagonist_ratio, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene TSHR. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints and this one serves a reporter gene function to understand target activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the gpcr intended target family, where the subfamily is thyrotropin-releasing hormone receptor.",, , , ,,,Active,91.4957322489304,4.57478661244652,61.065684400648585,1.78579722886748,1.7350029827067,68.4192302825,percent_activity,1.95424250943932,20,,1.47898239128346,1.10947786054375,1.25660482842333,20,gpcr
TOX21_VDR_BLA_Agonist_viability,"TOX21_VDR_BLA_Agonist_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.",, , , ,,,Active,39.6719748456184,1.4590651957592329,55.94867168959293,1.74778978014537,4.53166577259249,42.57830996435,percent_activity,1.90308998699194,27.1899946355549,"[""Only highest conc above baseline, active"",""Less than 50% efficacy"",""Only highest conc above baseline, active"",""Less than 50% efficacy""]",1.79005553501802,1.71242997179572,1.62850932297387,20,cell cycle
UKN4_HCS_LUHMES_cell_viability_dn,"The assay endpoint UKN4_HCS_LUHMES_cell_viability_dn was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of viability reporter, loss-of-signal activity can be used to understand viability effects. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is viability.",, , , ,,,Active,35.618126231290766,1.4247250492516306,147.94744308161034,2.1701074638180913,0.7078846407831513,32.50625146412286,percent_activity,2.47712125471966,25,"[""Less than 50% efficacy"",""Only one conc above baseline, active""]",2.220753301150995,2.0069738358831226,2.0401546960402603,,cell cycle
UKN4_HCS_LUHMES_neurite_outgrowth_dn,"The assay endpoint UKN4_HCS_LUHMES_neurite_outgrowth_dn was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of morphology reporter, loss-of-signal activity can be used to understand developmental effects. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the neurodevelopment intended target family, where the subfamily is neurite outgrowth.",, , , ,,,Active,60.14520434809306,2.4058081739237225,127.54710228544444,2.1056705964170996,8.469355519709685,62.528091744795,percent_activity,2.47712125471966,25,"[""Only one conc above baseline, active""]",2.086851504687427,2.088391326113124,1.9842722652914722,,neurodevelopment
UPITT_HCI_U2OS_AR_TIF2_Nucleoli_Antagonist,"Data from the assay component UPITT_HCI_U2OS_AR_TIF2_Nucleoli_Antagonist was analyzed into 1 assay endpoint. 
This assay endpoint, UPITT_HCI_U2OS_AR_TIF2_Nucleoli_Antagonist, was analyzed in the positive fitting direction relative to DHT as the baseline of activity. 
Using a type of binding reporter, measures of receptor for loss-of-signal activity can be used to understand the binding at the pathway-level as it relates to the gene AR.",, , , ,,,Active,68.90765151506,1.8144292210502555,50.746863989925664,1.705409209266,12.6591971211703,54.9272410730483,percent_activity,2,37.9775913635109,"[""Only highest conc above baseline, active"",""Only highest conc above baseline, active""]",1.75582662426912,1.75582662426912,1.16573173165665,19.99970054626465,nuclear receptor